




**Immunization  
Branch**

# Immunization Updates for Providers


Friday, February 7, 2025

9:00 am – 10:30 am

# Q&A



During today's webinar, please click and open the Q&A icon to ask your questions so CDPH panelists and subject matter experts (SMEs) can respond.



[Links are in blue and underlined](#)

# Housekeeping

## Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

[CDPH Weekly Immunization Updates for Providers](#).



To be added to the CDPH email messaging listserv for providers, please email your request to [blanca.corona@cdph.ca.gov](mailto:blanca.corona@cdph.ca.gov).



If you have post-webinar-related questions, please email [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov).


# Agenda: Friday, February 7, 2025

No.	Topic	Presenters (CDPH)	Time (AM)
1	Welcome and Announcements	Leslie Amani	9:00 – 9:05
2	COVID-19 Vaccine Administration Data	Hailey Maeda	9:05 – 9:10
3	Clinical Update	Floria Chi, MD	9:10 – 9:20
4	Vaccines for Children	Christina Sapad	9:20 – 9:30
5	Vaccines for Adults	Nisha Gandhi	9:30 – 9:35
6	Vaccine Management (My Turn / myCAvax)	Josh Pocus and Dan Conway	9:35 – 9:45
7	Resources and Q&A	Leslie Amani and CDPH SMEs	9:45 – 10:30

# Announcements

Leslie Amani, CDPH

# February is Black History Month



This Black History Month, we honor the [incredible contributions of Black women and men in the field of public health](#) [Facebook]. From breaking barriers to championing equity, these men and women have dedicated their lives to improving health outcomes and advocating for justice in every community.

Join CDPH as we celebrate the brilliance, resilience and dedication of Black public health professionals who shape a healthier future for us all.

Learn more about our [health equity work](#).



# Office Hour for Personalized Technical Assistance

Join My Turn subject matter experts (SMEs) for a 60-minute session to help add your clinics in real time, and get your questions answered by My Turn SMEs.

When: Friday, February 7, 2025

Time: 12:00 pm – 1:00 pm, PT

Register here: [My Turn Office Hour](#)





# Upcoming Webinar: Planning School Located Vaccine Events (SLVEs)

- Please join us **Wednesday, February 12, 2025, from 2:00 pm – 3:00 pm** for a webinar on planning school located vaccine events for **this** spring.
- While content will focus on adolescent events (6th graders) with Tdap, HPV and MCV4 vaccines, planning principles apply to all vaccines.
- Register at [Webinar Registration - Zoom](#)

ADOLESCENT  
SCHOOL-LOCATED  
VACCINATION EVENTS  
WEBINAR

**JOIN US**

**February 12, 2025 at 2:00 PM**

The purpose of this webinar is to support schools preparing for Spring school-located vaccination events. The webinar will focus on events targeting adolescents for HPV, Tdap and MCV4 vaccines.

This webinar will cover:

- Basic steps in for planning a school-located vaccination event
- An introduction to new web assets, including an updated school-located vaccine event web page and new adolescent-specific resources
- Lessons learned from guest speakers regarding their own Tdap/HPV/MCV4 vaccine event experiences at schools.

Anyone interested in coordinating school-located vaccine events, for adolescents or other populations, is encouraged to attend.

**REGISTER NOW**

OR SCAN QR CODE





# Webinar: Protecting Maternal and Infant Health

NFID Website with Webinar Information:

[Vaccines During Pregnancy: Protecting Maternal and Infant Health](#)

**When: Thursday, February 13, 2025**

**Time: 11:00 am, PT**

**Registration Link: [Webinar Registration Link](#)**

Join the National Foundation for Infectious Diseases (NFID) and partner organizations, the American College of Obstetricians and Gynecologists (ACOG), and the National Coalition for Infant Health (NCfIH), for a webinar discussion on strategies to help prevent infectious diseases and increase uptake of recommended vaccines during pregnancy. Speakers will discuss vaccines commonly recommended during pregnancy in the United States.



**Robert H. Hopkins Jr., MD**  
NFID Medical Director



**Kevin A. Ault, MD**  
Western Michigan  
University Homer Stryker  
MD School of Medicine



**Flor M. Muñoz, MD, MSc**  
Baylor College of Medicine



**National  
Foundation for  
Infectious  
Diseases**

[Subscribe to NFID Updates](#)



# California Immunization Coalition Summit

Tuesday, April 29 – Wednesday, April 30, 2025



[CA Immunization Coalition Summit 2025 Information](#)





# 2025 Immunization Block Schedule

## Routine Immunization Timing 2025

Suggested schedule to meet recommendations on time. [Refer to web version.](#)

Birth		6 months – 18+ years	
HepB <sup>1</sup>		COVID-19 vaccine(s) <sup>7</sup>	
RSV <sup>2</sup> (age: 0-8 months)		Flu vaccine, every fall <sup>8</sup>	

Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose
<b>2 months</b>		<b>4 months</b>		<b>6 months</b>		<b>12 months</b>		<b>15 months</b>		<b>18 months</b>	
DTaP (Diphtheria, Tetanus, Pertussis)		DTaP	1-2 months	DTaP	1-2 months	HepA <sup>9</sup> (age: 12-23 months)		DTaP <sup>13</sup> (age: 15-18 months)	6-12 months	HepA	6-18 months
Polio (IPV)		Polio (IPV)	1-2 months	Polio (age: 6-18 months)	1-14 months	MMR <sup>9,10,11</sup> (ages 12-15 months)					
HepB <sup>3</sup> (age: 1-2 months)	1-2 months after birth dose	HepB <sup>3</sup> if 1st dose given at 2 months	1-2 months	HepB <sup>3</sup> (age: 6-18 months)	2-12 months and ≥4 months after 1st dose	Var <sup>11</sup> (age: 12-15 months)					
Hib <sup>4</sup> (Hib meningitis)		Hib	1-2 months	Hib <sup>6</sup>	1-2 months	Hib (age: 12-15 months)	2-8 months				
PCV (Pneumo)		PCV	1-2 months	PCV	1-2 months	PCV <sup>12</sup> (age: 12-15 months)	8 weeks				
RV <sup>5</sup> (Rotavirus)		RV <sup>5</sup>	4-10 weeks	RV <sup>5</sup> if RotaTeq used for doses 1 or 2	4-10 weeks						

**Age 4-6 years**  
DTaP  
Polio (IPV)  
MMR<sup>10,11</sup>  
Varicella<sup>11</sup>

**Age 11-12 years**  
HPV<sup>14</sup> (2 doses, **can start at age 9**)  
MenACWY (MCV4)  
Tdap

**Age 16 years**  
MenACWY (MCV4)  
MenB<sup>15</sup>

**CDPH** California Kids Love them. Immunize them.  
California Department of Public Health, Immunization Branch • EZIZ.org IMM-395 (1/25)

## Calendario de vacunación de rutina para el 2025

Esquema sugerido para cumplir con las recomendaciones a tiempo. [Consulte versión en línea en inglés.](#)

Al nacer		6 meses - 18+ años	
HepB <sup>1</sup>		Vacuna(s) contra el COVID-19 <sup>7</sup>	
VRS <sup>2</sup> (edad: 0-8 meses)		Vacuna contra la influenza cada otoño <sup>8</sup>	

Edad	Intervalo desde la dosis anterior	Edad	Intervalo desde la dosis anterior	Edad	Intervalo desde la dosis anterior	Edad	Intervalo desde la dosis anterior	Edad	Intervalo desde la dosis anterior	Edad	Intervalo desde la dosis anterior
<b>2 meses</b>		<b>4 meses</b>		<b>6 meses</b>		<b>12 meses</b>		<b>15 meses</b>		<b>18 meses</b>	
DTaP (Difteria, tétanos y tosferina)		DTaP	1-2 meses	DTaP	1-2 meses	HepA <sup>9</sup> (edad: 12-23 meses)		DTaP <sup>13</sup> (edad: 15-18 meses)	6-12 meses	HepA	6-18 meses
Polio (IPV)		Polio (IPV)	1-2 meses	Polio (edad: 6-18 meses)	1-14 meses	MMR <sup>10,11</sup> (edad: 12-15 meses)					
HepB <sup>3</sup> (edad: 1-2 meses)	1-2 meses después de la dosis de nacimiento	HepB <sup>3</sup> si la 1ra dosis se puso a los 2 meses de edad	1-2 meses	HepB <sup>3</sup> (edad: 6-18 meses)	2-12 meses y por lo menos 4 meses después de la dosis	Var <sup>11</sup> (edad: 12-15 meses)					
Hib <sup>4</sup> (Haemophilus influenzae tipo b)		Hib	1-2 meses	Hib <sup>6</sup>	1-2 meses	Hib (edad: 12-15 meses)	2-8 meses				
PCV (Neumococo)		PCV	1-2 meses	PCV	1-2 meses	PCV <sup>12</sup> (edad: 12-15 meses)	8 semanas				
RV <sup>5</sup> (Rotavirus)		RV <sup>5</sup>	4-10 semanas	RV <sup>5</sup> si RotaTeq se usó para la 1ª o 2ª dosis	4-10 semanas						

**4-6 años**  
DTaP  
Polio (IPV)  
MMR (sarampión, paperas y rubéola)<sup>10,11</sup>  
Varicela<sup>11</sup>

**11-12 años**  
VPH<sup>14</sup> (2 dosis - **se puede empezar a los 9 años**)  
MenACWY (MCV4)  
Tdap

**16 años**  
MenACWY (MCV4)  
MenB<sup>15</sup>

**CDPH** Niños de California. Amémoslos. Vacunémoslos.  
California Department of Public Health, Immunization Branch • EZIZ.org IMM-395 (2/25)

Now in Spanish!

[Routine Immunization Timing Block Schedule](#)

[Calendario de Vacunacion de Rutina para el 2025](#)

# Influenza and Respiratory Disease Resources

The screenshot shows the EZIZ website interface. At the top, it says "A one-stop shop for immunization training and resources." The main navigation menu includes: Home, Vaccine Programs, Vaccine Management, Storage Units, Temperature Monitoring, Training & Webinars, Clinic Resources, and Patient Resources. The "Patient Resources" section is expanded, showing categories like "Flu & Respiratory Disease Prevention Promotional Materials" with a "WE'RE STRONGER WHEN WE'RE ALL PROTECTED Get Your Flu Shot!" banner, "Resources for Patients" with sub-sections for Audiences, Vaccines and Diseases, and Related Links, "School-aged Children", "All Ages", "Parents and Caregivers", "Pregnant People", "Older Adults (60+)", and "Job Aids for Healthcare Workers".

## Flu and Respiratory Disease Prevention Promotional Materials

The screenshot shows a video player titled "The Story of Isabella Darling". The video content includes a woman in a hospital bed with a nasal cannula and a family of three smiling. Text overlay on the video reads: "Protect yourself and your loved ones by getting annual flu vaccine".

### ShotByShot: Isabella's Story

We have two NEW tools to help promote flu vaccination:

- [Isabella's Story](#) – this new [ShotbyShot.org](#) story emphasizes the importance of flu vaccination. Isabella, who wasn't vaccinated, faced severe complications and now lives with permanent disabilities due to the flu. Share her story with patients.
- [Template Letter](#) – this is a customizable letter to remind patients to schedule their flu vaccine. (English / Spanish)

# American Heart Month Communications Toolkit



## Includes:

1. Heart Health Quick Facts
2. Spanish and English Tools
3. Caring About Your Heart Health
4. Resources for Cardiovascular Health Care Teams
5. Social Media



[CDC: American Heart Month Communications Toolkit](#)

# CDPH Office of Communications Toolkits



## Infectious Diseases

Infectious diseases are illnesses caused by viruses, bacteria, fungi, or parasites that can spread from person to person or from animals to humans. Encourage your communities to prevent infectious diseases from spreading by washing their hands often and staying up to date on recommended vaccines.

Use these toolkits to copy, download and share social media messages, graphics and outreach materials focused on infectious diseases to increase awareness and promote health education about preventing the spread of illnesses

[CDPH Communication Toolkits](#)

# H5N1 Resources

## CDPH Information for Health Care Professionals: Avian Influenza A (H5N1)

The screenshot shows the CDPH website interface. At the top left is the CDPH logo with the text 'California Department of Public Health'. To the right is a search bar and navigation links: 'I am looking for', 'I am a', 'Programs', and 'A-Z Index'. Below the navigation is a breadcrumb trail: 'Home | Programs | Center for Infectious Diseases | Division of Communicable Disease Control | Avian Influenza A(H5N1) Information for Health Professionals'. A dark blue banner at the top of the main content area reads 'AVIAN INFLUENZA A(H5N1)'. On the left side, there is a vertical menu with links: 'Bird Flu', 'Bird Flu Testing and Flu Vaccine Clinics', 'Guidance for People with Possible or Confirmed Bird Flu Infection', 'Novel Flu', 'News and Hot Topics', 'CAHANS', and 'Information for Local Health Departments'. The main content area is titled 'Information for Health Professionals' and features a 'Key Messages' section with a light blue background containing five bullet points.

**CDPH**  
California Department of Public Health

Q

I am looking for  
I am a  
Programs  
A-Z Index

Home | Programs | Center for Infectious Diseases | Division of Communicable Disease Control | Avian Influenza A(H5N1) Information for Health Professionals

## AVIAN INFLUENZA A(H5N1)

Bird Flu

Bird Flu Testing and Flu Vaccine Clinics

Guidance for People with Possible or Confirmed Bird Flu Infection

Novel Flu

News and Hot Topics

CAHANS

Information for Local Health Departments

### Information for Health Professionals

#### Key Messages

- Healthcare providers should consider avian influenza A in persons with acute respiratory symptoms and/or conjunctivitis and recent exposure to animals or humans suspected or confirmed to have avian influenza A OR recent consumption of raw dairy products. Of note, all cases among California dairy workers have had conjunctivitis.
- Providers should immediately report any suspected human avian influenza A infections to their [local health departments](#).
- Testing of respiratory and conjunctival specimens for avian influenza A is available at some public health laboratories and two commercial laboratories.
- Antiviral treatment is recommended for patients suspected or confirmed to have avian influenza A infection and antiviral prophylaxis is recommended for their close (e.g., household) contacts.
- Healthcare providers should follow [standard, contact, and airborne precautions](#) when caring for patients suspected of having avian influenza A infection.

[CDPH Webpage: Avian Influenza A \(H5N1\)](#)

# Message: Importance of Prenatal Vaccines

It's peak respiratory virus season! [If you're pregnant, you can help protect your baby](#) from the start by making sure you're up to date on the following vaccinations:

- Updated 2024 – 2025 flu and COVID-19
- Tdap (at 27 – 36 weeks pregnant)

Getting vaccinated is a safe way to protect your baby in early life when they are most vulnerable to getting very sick. Talk to your health care provider or visit [MyTurn.ca.gov](https://www.myturn.ca.gov) to schedule vaccine appointments.

Learn more about [immunizations for a healthy pregnancy](#) and visit the [Pregnancy and Immunizations Communications Toolkit](#) for more messages to share.



[CDPH Office of Communications Pregnancy Toolkit](#).



# COVID-19 Vaccines and Pregnancy

**Las vacunas contra el COVID-19 y el embarazo**

La vacunación contra el COVID-19 durante el embarazo es segura, eficaz y gratuita.

**Es importante conservar la salud durante el embarazo.**

Si está embarazada, manténgase al día con su [vacunación contra el COVID-19](#), lo cual incluye recibir la vacuna bivalente actualizada contra el COVID-19 si aún no lo ha hecho.

Tiene más probabilidades de enfermarse gravemente de COVID-19 que las personas que no están embarazadas.

El COVID-19 puede causar complicaciones tales como:

- Hospitalización
- Admisión a la unidad de cuidados intensivos (UCI)
- Necesidad de respirador u otro equipo especial para respirar
- Muerte
- Nacimiento prematuro (antes de las 37 semanas de embarazo)
- Muerte fetal

La vacunación contra el COVID-19 durante el embarazo ayudará a proteger a su bebé luego del nacimiento.

Protéjase y proteja a su familia hoy mismo. Visite [MyTurn.ca.gov](#) para programar una cita de vacunación o llame a su proveedor de salud para hacerle las preguntas que necesite sobre las vacunas contra el COVID-19.

Escanee el código QR para acceder a los enlaces de este folleto.



COVID-19 Vaccines and Pregnancy • Spanish • May, 2023 • © 2023, California Department of Public Health

[Las Vacunas Contra el COVID-19 y el Embarazo](#)

**COVID-19 Vaccines and Pregnancy**

COVID-19 vaccination during pregnancy is safe and effective.

**It's important to stay healthy during pregnancy.**

If you're pregnant, stay up to date with your [COVID-19 vaccines](#).

You're more likely to get very sick from COVID-19 than people who aren't pregnant.

COVID-19 can cause complications such as:

- Hospitalization
- Admission to an intensive care unit (ICU)
- Needing a ventilator or special equipment to breathe
- Death
- Premature birth (before 37 weeks of pregnancy)
- Stillbirth

Getting the COVID-19 vaccine while pregnant will help protect your baby as soon as they are born.

Protect yourself and your family today. Visit [MyTurn.ca.gov](#) to schedule your vaccine appointment or call a health care provider to discuss any questions you have about the COVID-19 vaccines.

Scan the QR code to access the links on this flyer.



August, 2023 • © 2023, California Department of Public Health

[COVID-19 and Pregnancy Fact Sheet](#)

# **COVID-19 Vaccine Administration Data**

Hailey Maeda, CDPH

# COVID-19 Vaccine Administration Summary

as of February 3, 2025

**102,048,351**

Total Doses Administered



**5,130,362**

2024-2025 COVID-19 Recipients

**13.1%**

Statewide Up-to-Date

Daily Doses Administered: **Statewide**




# Trends in COVID-19 Vaccine Administration

as of February 3, 2024

Doses Administered by Age Group, Past 4 Weeks

Under 5	5-11	12-17	18-49	50-64	65+
10,671 doses per week			20,535 doses per week		29,955 doses per week



**CDC recommends the 2024-25 COVID-19 vaccine for everyone 6 months and older**

**An updated vaccine protects against:**

- ✓ COVID-19 variants spreading now
- ✓ Severe illness, hospitalization, and death


[bit.ly/mm7337e2](https://bit.ly/mm7337e2)  
 SEPTEMBER 10, 2024

# COVID-19 Vaccine Uptake Comparison

as of February 3, 2025

Current vs Last Year's COVID-19 Vaccine Dose Uptake in 164 days since EUA

■ Updated 2024-2025 Doses ■ Updated 2023-2024 Doses



Currently COVID-19 Vaccine uptake is tracking closely to last year (-232K doses)


# COVID-19 Vaccination Overview

as of February 3, 2025


% of Population Up-to-Date: Statewide 13.1%

Above State Average | Below State Average


By County




By HPI Quartile



By Race/Ethnicity



By Age Group



[Public Dashboard Link](#)

# System Notes

- Up-to-Date status is defined as at least one dose of the updated 2024 – 2025 COVID-19 vaccine.
- 2024 – 2025 COVID-19 vaccine data is available on the Public dashboard.
  - Updated monthly
- Email [cdphvaccinatedatateam@cdph.ca.gov](mailto:cdphvaccinatedatateam@cdph.ca.gov) for questions and comments.

[Public Dashboard Link](#)

# Clinical Updates

Floria Chi, MD








# CDPH Respiratory Virus Report

(as of 1/25/25)

## - Report Highlights -

The 2024-2025 Respiratory Virus Season covers June 30, 2024 through June 28, 2025.

	COVID-19	FLU	RSV
 Test Positivity (change)	2.4% (0.0)	26.3% (3.0)	5.7% (-0.7)
 New Admissions Rate per 100,000 Persons (change)	2.2 (-0.1)	9.5 (0.9)	N/A
 Percent of Total Deaths (change)	1.5% (1.0)	2.4% (1.0)	0.0% (-0.3)
 Total Season Pediatric Deaths (new)	3 (0)	10 (3)	2 (0)
 Wastewater Concentrations (trend)	MEDIUM (PLATEAUING)	N/A	N/A


## Key Messages:

- **Activity**
  - Influenza: high and increasing
  - RSV: low and decreasing
  - COVID-19: low
- **Influenza subtypes from + tests**
  - Majority are type A, with both H1 and H3 strains circulating.
  - Type B <5%
- **Vaccination coverage**
  - Only a small percentage of eligible Californians have received the appropriate respiratory virus vaccines.

[Report Data](#) from January 19 – 25, 2025


# Influenza: High and Increasing (CA)

Figure 2. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2020/2021 Season to Date




# Influenza: Hospitalizations (CA)

Figure 6. Rate of Influenza Admissions from NHSN from November 1, 2024 to Date



# RSV: Decreasing (CA)


Figure 3. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2020/2021 Season to Date



# RSV: Infant Hospitalizations (National, CDC)


[Respiratory Virus-Associated Hospitalization Rates](#) for Infants <1 year (as of 1/31/25)

RSV accounts for nearly 80% of all infant respiratory hospitalizations.



# COVID-19: Low (CA)

Figure 1. Percentage of SARS-CoV-2 Detections from Test Results Received through Electronic Laboratory Reporting, 2022/2023 Season to Date



# Timing and Administration of COVID-19, Influenza, and RSV Immunizations

	AUG	SEP	OCT	NOV	DEC	JAN	FEB	MAR	APR	MAY	JUN	JUL
<b>COVID-19</b>	Administer as soon as available		However, can be given any time of the year to people eligible for vaccination									
<b>Flu</b>		Ideally administer early fall <sup>1</sup>										
<b>Older adults RSV vaccine</b>		Ideally administer late summer/ early fall										
<b>Maternal RSV vaccine</b>		Administer September through January in most of the continental U.S. <sup>2</sup>										
<b>OR</b>												
<b>Infant RSV immunization, nirsevimab</b>			Ideally administer October through March in most of the continental U.S. <sup>2</sup>									

<sup>1</sup> Children who need 2 doses should receive their first dose as soon as possible (including during July and August). One dose of flu vaccine can be considered for pregnant people in their third trimester during July and August.




<sup>2</sup> In jurisdictions with RSV seasonality that differs from most of the continental United States, including Alaska, southern Florida, Guam, Hawaii, Puerto Rico, U.S.-affiliated Pacific Islands, and U.S. Virgin Islands, providers should follow state, local, or territorial guidance. However, nirsevimab may be administered outside of routine seasonal administration (ie., October through March) based on local RSV activity and other special circumstances.


# It's Not Too Late to Vaccinate!

- Everyone 6 months and older should get **updated COVID-19 and influenza vaccines.**
- Infants and older adults who are eligible should get **RSV immunization.**
- Immunizations may be co-administered at the same visit.

[RSVseasonImmunizationRecommendations.pdf](#)

## RSV Season Immunization Recommendations

	July	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	April	May	Jun
<b>Infants &amp; Children (Nirsevimab)*</b> 				October 1 – March 31*								
<b>Pregnant people (Abrysvo)*</b> 			September 1 – January 31 between 32-36 weeks gestation*									
<b>Adults 75+, and 60-74 at increased risk (Abrysvo, Arexvy, mRESVIA)</b> 	Offer to eligible, unvaccinated adults. CDC encourages healthcare providers to maximize the benefit of RSV vaccination by offering in late summer or early fall.											

 Recommended immunization timing

\*If continuing to immunize outside recommended timeframe, make sure to:

1. Check with insurers to ensure reimbursement. Keep remaining doses for next RSV season.
2. Unused and unexpired supply of VFC Nirsevimab or Abrysvo cannot be returned to McKesson. Label these doses as **"Keep for Fall."**



# RSV Immunization for Infants and Toddlers

Administer nirsevimab to:


- Infants <8 months if prenatal vaccination was not given\*
  - Within the first week of life, *ideally in hospital or at first outpatient pediatric visit*

- High-risk children 8 – 19 months old

\*If unable to confirm if prenatal RSV vaccination was given, consider:

- Asking birth parent to look up their Digital Vaccine Record: [mydvr.cdph.ca.gov](https://mydvr.cdph.ca.gov)
- Checking the [California Immunization Registry \(CAIR\)](#)


## Prenatal Infographic



Additional resources:

[IMM-1480 Nirsevimab \(Beyfortus\) Guide \(CDPH\)](#)  
[RSV Immunization Guidance for Infants/Children \(CDC\)](#)

# The Time to Recall Patients for Flu Vaccine is Now



Children 6 months through 8 years who received less than 2 doses of flu vaccine in previous seasons need **2 doses**, 4 weeks apart.

## Flu Vaccine Communication Templates

- [Provider to Patient Letter Template](#)
- [Schools to Parent Letter Template](#)
- [Schools Robocall Script Template](#)

[Flu is Surging Infographic](#)

[Flu & Respiratory Disease Prevention Promotional Materials](#)

# COVID-19 Vaccine: 2nd Dose for 65+ and Immunocompromised

Everyone 6 months and older should receive an updated 2024 – 2025 COVID-19 vaccine if they haven't already.

Those who are ≥65 years or immunocompromised should also receive a **second dose 6 months\*** after their first.

\*Minimum interval 2 months.

**COVID-19 Vaccine Timing 2024-25 – Routine Schedule**

For online version and details view [Interim Clinical Considerations for Use of COVID-19 Vaccines](#). Schedule is subject to change.

Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2024-25 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3-8 weeks → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8 weeks 1, ≥8 weeks 2 If ≥2 prior doses, then: ≥8 weeks 1
	Moderna–Pediatric*	1st Dose → 4-8 weeks → 2nd Dose	If 1 prior dose, then: 4-8 weeks 1 If ≥2 prior doses then: ≥8 weeks 1
5–11 years	Moderna–Pediatric*	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months 1, 2024-25 Moderna/Pfizer/Novavax
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	If 1 or more prior doses (of any of the brands), then*: Ages 12-64 years: ≥2 months 1, 2024-25 Moderna/Pfizer/Novavax; Ages 65+ years: ≥2 months 1, 6 months* 2
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax	1st Dose → 3-8 weeks → 2nd Dose	

\* See CDC recommendations for children transitioning from a younger to older age group  
† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.  
\*\* An 8-week interval may be preferable for some people, especially for males 12-39 years.  
‡ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).  
§ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.  
¶ Minimum interval 2 months.  
Ⓛ If >8 weeks passed since the first Novavax dose, any 2024–25 COVID-19 vaccine (Moderna/Pfizer/Novavax) may be given.

CDPH  
California Department of Public Health, Immunization Branch IMM-1396 (11/4/24) Page 1 of 2

**COVID-19 Vaccine Timing 2024-25 if Moderately/Severely Immunocompromised**

Age	Vaccine	If unvaccinated:	If had any prior doses give 2024-25 doses:
6 months–4 years	Pfizer–Infant/Toddler	1st Dose → 3 weeks → 2nd Dose → ≥8 weeks → 3rd Dose → 6 months → Additional Dose(s)*	1 prior dose: 3 w 1, ≥8 w 2, 6 m† ≥2 prior doses: ≥8 w 1, Additional Dose(s)*
	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → 6 months → Additional Dose(s)*	1 prior dose: 4 w 1, ≥4 w 2, 6 m† 2 prior doses: ≥4 w 1, Additional Dose(s)*
5–11 years	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → 6 months → Additional Dose(s)*	1 prior dose: 4 w 1, ≥4 w 2, 6 m† 2 prior doses: ≥4 w 1, Additional Dose(s)*
	Pfizer–Pediatric	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → 6 months → Additional Dose(s)*	1 prior dose: 3 w 1, ≥4 w 2, 6 m† 2 prior doses: ≥4 w 1, Additional Dose(s)*
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → 6 months → Additional Dose(s)*	1 prior dose: 3 w 1, ≥4 w 2, 6 m† 2 prior doses: ≥4 w 1, Additional Dose(s)* ≥3 prior doses**: ≥8 w 1, Additional Dose(s)*
	Moderna–Adol/Adult (Spikevax)	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → 6 months → Additional Dose(s)*	1 prior dose: 4 w 1, ≥4 w 2, 6 m† 2 prior doses: ≥4 w 1, Additional Dose(s)* ≥3 prior doses**: ≥8 w 1, Additional Dose(s)*
	Novavax	1st Dose → 3 weeks → 2nd Dose → 6 months → Additional Dose(s)*	1 prior dose: 3 w 1, ≥4 w 2, 6 m† 2 prior doses: ≥4 w 1, Additional Dose(s)* ≥3 prior doses**: ≥8 w 1, Additional Dose(s)*

Additional doses may be given under shared clinical decision-making at a minimum interval of 2 months. See Table 2 for viral and dosage.  
† 5-11 years may be given Moderna or Pfizer after ≥3 prior doses. Ages 12+ years may be given Moderna, Pfizer, or Novavax. Minimum interval 2 months.  
\*\* 8 weeks passed since the first Novavax dose, any 2024–25 COVID-19 vaccine (Moderna/Pfizer/Novavax) may be given.

CDPH  
California Department of Public Health, Immunization Branch IMM-1396 (11/4/24) Page 2 of 2

## IMM-1396 COVID-19 Vaccine Timing Chart

# Updated Pneumococcal Timing Guides

## Pneumococcal Vaccine Timing—For Children

### Age 2-23 Months View web version of this schedule.

**Standard**

<b>PCV15</b> Vaxneuvance® or PCV20 Pprevnar 20®	<b>PCV15</b> Vaxneuvance® or PCV20 Pprevnar 20®	<b>PCV15</b> Vaxneuvance® or PCV20 Pprevnar 20®	<b>PCV15</b> Vaxneuvance® or PCV20 Pprevnar 20®
Age: <b>2 months</b>	Age: <b>4 months</b>	Age: <b>6 months</b>	Age: <b>12–15 months</b>

• Catch-up: Healthy children 24–59 months: 1–4 doses PCV15 or PCV20 depending on age and timing of past doses.

### Age 2–18 Years With Underlying Condition(s)

- Children 2–18 years with any risk who have received all recommended doses before 6 years do not need further doses if they have received at least one dose of PCV20. If they have received PCV13 or PCV15, they should receive a dose of PCV20 OR PPSV23 (at least eight weeks after the prior dose of pneumococcal conjugate vaccine).
- Children 6–18 years with any risk who have not received any doses of PCV13, PCV15 or PCV20 should receive a single dose of PCV15 or PCV20. When PCV15 is used, it should be followed by a dose of PPSV23 >8 weeks later if not previously given.
- Children younger than 6 years of age should have received the standard or catch-up doses of PCV15 or PCV20. If PCV13 or PCV15 is used, follow with PPSV23 eight weeks later.
- Catch-up for Children 24–71 months with underlying conditions: 1–4 doses PCV15 or PCV20 depending on age and timing of past doses.

**Risk Categories:**

**Chronic conditions:**

- Chronic heart disease (particularly failure or cyanotic disease)
- Chronic kidney disease
- Chronic liver disease
- Chronic lung disease (including moderate persistent or severe persistent asthma)
- Diabetes mellitus
- CSF leaks or Cochlear implants

**Immunocompromise:**

- On maintenance dialysis or nephrotic syndrome
- Asplenia or splenic dysfunction
- Immunodeficiency (including B- to T-cell deficiency, complement deficiency and phagocytic disorders excluding CGD)
- Diseases and conditions treated with immunosuppressive drugs or radiation treatments (including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease)
- HIV infection
- Sickle cell disease or other hemoglobinopathies
- Solid organ transplant

**PCV 20**  
Pprevnar 20®

OR

**PCV 15**  
Vaxneuvance®

→

8 weeks

**PPSV<sup>†</sup> 23**  
Pneumovax® 23

1. When PPSV23 is used instead of PCV20 for children aged 2–18 years with an immunocompromising condition, either PCV20 or a second PPSV23 dose is recommended ≥5 years after the first PPSV23 dose.

CDPH

For further details, see CDC's [Pneumococcal Vaccine Recommendations](#).  
California Department of Public Health, Immunization Branch [www.EZIZ.org](http://www.EZIZ.org)

IMM-1159 (1/25)

## Pneumococcal Vaccine Timing for Adults

### High-Risk<sup>^</sup> 19–49 Years and All 50+ Years

**A. Unknown or No Prior Doses or PCV7 only at any age**

<p><b>Option A1:</b></p> <div style="border: 1px solid #0056b3; background-color: #0056b3; color: white; padding: 5px; text-align: center; margin-bottom: 5px;"><b>PCV21</b> Capvaxime™</div> <p style="font-size: x-small;">(PPSV23 not needed)</p>	<p><b>Option A2:</b></p> <div style="border: 1px solid #0056b3; background-color: #0056b3; color: white; padding: 5px; text-align: center; margin-bottom: 5px;"><b>PCV20</b> Pprevnar 20®</div> <p style="font-size: x-small;">(PPSV23 not needed)</p>	<p><b>Option A3:</b></p> <div style="border: 1px solid #0056b3; background-color: #0056b3; color: white; padding: 5px; text-align: center; margin-bottom: 5px;"><b>PCV15</b> Vaxneuvance®</div>
<p>OR</p>		

≥1 year interval:  
if healthy 50+, or 19+ with chronic health condition<sup>^</sup>

Consider ≥8 week interval:  
if 19+ at high risk<sup>\*</sup>

**PPSV23<sup>§</sup>**  
Pneumovax® 23

DO NOT administer PCV15 and PPSV23 at the same visit.

**B. Previously Received PPSV23 only**

≥1 year since PPSV23

**PCV21**  
Capvaxime™

OR

**PCV20**  
Pprevnar 20®

OR

**PCV15**  
Vaxneuvance®

**C. Previously Received PCV13 only<sup>†</sup>**

≥1 year since PCV13

**PCV21**  
Capvaxime™

OR

**PCV20**  
Pprevnar 20®

**D. Previously Received PCV13 and PPSV23 in Any Order<sup>†</sup>**

≥5 years since last pneumococcal dose and

- 19–49 years old with high risk condition or
- Received PPSV23 at <65 years<sup>\*\*</sup>

**PCV21**  
Capvaxime™

OR

**PCV20**  
Pprevnar 20®

\*\* If PPSV23 given at or after 65 years of age, PCV 20 or PCV21 may be given, under shared clinical decision making.

**\* High risk, including immunocompromising conditions, CSF leak, or cochlear implant**  
In Option A3, consider a minimum interval of 8 weeks between PCV15 and PPSV23 for these conditions:

- Asplenia, congenital or acquired
- Immunodeficiency, congenital or acquired
- CSF leak
- Latrogenic immunosuppression
- Cochlear implant
- Solid organ transplant
- Chronic renal failure
- Generalized malignancy
- Nephrotic syndrome
- Leukemia
- Sickle cell disease or other hemoglobinopathies
- Lymphoma
- HIV infection
- Hodgkin disease
- Multiple myeloma

**^ Chronic health conditions**  
In Option A3, minimum interval of 1 year between PCV15 and PPSV23 for these conditions:

- Alcoholism
- Chronic heart disease
- Cigarette smoking
- Chronic liver disease
- Diabetes mellitus
- Chronic lung disease

**§** If PPSV23 is not available, PCV20 or PCV21 may be used.

**† See additional guidance from CDC at:**

- [Pneumococcal Vaccine Timing for Adults](#)
- [ACIP Pneumococcal Vaccine Recommendations](#)

CDPH

California Department of Public Health, Immunization Branch IMM-1152 (1/7/25)

[Child Timing Guide \(IMM-1159\)](#)

[Adult Timing Guide \(IMM-1152\)](#)

# Updated Meningococcal Timing Guides

**For Health Professionals** [View web version of this schedule.](#)

## Meningococcal Vaccines for Adolescents & Young Adults: Routine Risk<sup>1</sup>

**CDPH**

### Routine MenACWY<sup>2,3</sup> for 11-18 years **2 Doses**

**MenACWY** MenQuadfi<sup>®</sup> or Menveo<sup>®</sup> **8 weeks min.** **MenACWY** MenQuadfi<sup>®</sup> or Menveo<sup>®</sup>

**Ages 11 or 12 years** **Age 16 years**

**Catch-up<sup>4</sup>:**

- Ages 13-15 years: 1 dose now and booster at age 16-18 years.
- Ages 16-18 years: 1 dose

### Shared Clinical Decision-Making MenB<sup>2</sup> for 16-23 years **2 Doses**

Preferred age is 16-18 years

**MenB** Bexsero<sup>®</sup> **At least 6 months** **MenB** Bexsero<sup>®</sup>

**MenB** Trumenba<sup>®</sup> **At least 6 months** **MenB<sup>5</sup>** Trumenba<sup>®</sup>

- If dose 2 is administered earlier than 6 months, administer 3<sup>rd</sup> dose at least 4 months after dose 2.
- To optimize rapid protection (e.g., for students starting college in less than 6 months), a 3-dose series (0, 1-2, 6 months) may be administered.

Use the same brand of MenB vaccine for each dose in the series.

### Pentavalent Vaccine (MenABCWY)<sup>2</sup> Suggested Dosing for 11-23 years **3 Doses**

**MenACWY** MenQuadfi<sup>®</sup> or Menveo<sup>®</sup> **8 weeks min.** **MenABCWY** Penbraya **At least 6 months** **MenB<sup>5</sup>** Trumenba<sup>®</sup>

**Ages 11 or 12 years** **Age 16 years**

If a patient receives Penbraya, which includes Trumenba, subsequent MenB dose(s) must be Trumenba since MenB brands are not interchangeable

**Notes:**

1. For **high-risk populations** (increased exposure to meningococcal disease, HIV infection, complement deficiencies or asplenia), (EZIZ.org/assets/docs/IMM-1218.pdf) (CDC.gov/mmwr/volumes/69/rr/rr6909a1.htm#T3\_down)
2. MenACWY and MenB vaccines each protect against different serogroups. They may be given at the same visit. If a patient is receiving MenACWY and MenB vaccines at the same visit, **MenABCWY** may be given instead.
3. MenACWY (MCV4) vaccines protect against serogroups A, C, W-135, and Y.
4. One dose of MenACWY is also recommended for previously unvaccinated or incompletely vaccinated first-year college students living in residence halls and military recruits and may be administered to persons aged 19-21 yrs. who have not received a dose after their 16th birthday.
5. A two-dose series is recommended for persons who are not at increased risk for meningococcal disease. A three-dose (0, 1-2, and 6 months) series is recommended for **persons at increased risk, including during outbreaks of serogroup B disease** (EZIZ.org/assets/docs/IMM-1218.pdf).

California Department of Public Health, Immunization Branch **EZIZ.org** IMM-1217 (1/25)

## Routine Schedule (IMM-1217)

## Meningococcal Vaccines—High-Risk Populations

[View web version of this schedule.](#)

Note that different vaccines protect against different serogroups. Follow the schedule according to age and these abbreviations for risk groups.

**Exp:** Increased Exposure to meningococcal serogroups covered by vaccines (due to outbreaks<sup>1</sup>, travel to affected areas [e.g. the Hajj], lab exposure)

**CD:** Persistent Complement component Deficiencies (including persons taking complement inhibitor [e.g., eculizumab<sup>®</sup> or ravulizumab<sup>®</sup>])

**Asp:** Functional or Anatomic Asplenia (including sickle cell disease)

**HIV:** HIV Infection

Age at first dose	Exp	CD	Asp	HIV	1) MenACWY vaccines <sup>2,6</sup>	Boosters for those who remain at increased risk <sup>3,6</sup>			
<b>2-6 months<sup>4</sup></b>	✓	✓	✓	✓	2 months: ACWY-CRM <sup>®</sup> Menveo <sup>®</sup> 4 months: ACWY-CRM <sup>®</sup> Menveo <sup>®</sup> 6 months: ACWY-CRM <sup>®</sup> Menveo <sup>®</sup> 12-15 months: ACWY-CRM <sup>®</sup> Menveo <sup>®</sup>	If primary dose(s) given when younger than 7 years: 3 years: ACWY-CRM or -TT Menveo <sup>®</sup> or MenQuadfi <sup>®</sup> → Every 5 years: ACWY-CRM or -TT Menveo <sup>®</sup> or MenQuadfi <sup>®</sup>			
<b>7-23 months</b>	✓	✓	✓	✓	ACWY-CRM <sup>®</sup> Menveo <sup>®</sup> → 3 months → ACWY-CRM <sup>®</sup> Menveo <sup>®</sup>				
<b>2 years and older</b>	✓	✓	✓	✓	ACWY-CRM or -TT Menveo <sup>®</sup> or MenQuadfi <sup>®</sup> → 2 months → ACWY-CRM or -TT Menveo <sup>®</sup> or MenQuadfi <sup>®</sup>	If primary dose(s) given at age 7 years or older: Every 5 years: ACWY-CRM or -TT Menveo <sup>®</sup> or MenQuadfi <sup>®</sup>			
					ACWY-CRM or -TT Menveo <sup>®</sup> or MenQuadfi <sup>®</sup>				
<b>10 years and older</b>	✓	✓	✓	✓	1st dose: MenB-4C Bexsero <sup>®</sup> → 1-2 months → 2nd dose: MenB-4C Bexsero <sup>®</sup> → 6 months between 1st and 3rd dose → 3rd dose: MenB-4C Bexsero <sup>®</sup>	<b>Boosters</b> Lab exposure, complement deficiency, asplenia: 1 year → MenB → Every 2-3 years → MenB			
					1st dose: MenB-FHbp Trumenba <sup>®</sup> → 1-2 months → 2nd dose: MenB-FHbp Trumenba <sup>®</sup> → 6 months between 1st and 3rd dose → 3rd dose: MenB-FHbp Trumenba <sup>®</sup>				
					lab	✓	✓		
					out-break				Increased risk during an outbreak: (Interval of ≥6 months may be considered depending on the outbreak.) 1 year → MenB

**2) Also give MenB vaccine—may be given at same time as MenACWY vaccine. Use the same brand for each dose in the series.<sup>5</sup>**

**View detailed meningococcal recommendations** (CDC.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html) **and routine recommendations** (EZIZ.org/assets/docs/IMM-1217.pdf).

1. For information on outbreaks visit the **CDPH website** (CDPH.CA.gov/Programs/CID/DCDC/Pages/Immunization/meningococcal.aspx).
2. Abbreviations: ACWY/ACWY-CRM/ACWY-TT = MenACWY = MCV4
3. If no longer at high risk by age 10, administer additional two doses of MenACWY according to the regular adolescent schedule at age 11-12 years and age 16 years.
4. If MenACWY-CRM is initiated at ages 3-6 months, catch-up vaccination includes doses at intervals of 8 weeks until the infant is aged ≥7 months, at which time an additional dose is administered at age ≥7 months, followed by a dose at least 12 weeks later and after the 1st birthday.
5. Minimum age 12 months.
6. If a patient aged 10 years and older is receiving MenACWY and MenB vaccines at the same visit, MenABCWY may be given instead. The minimum interval between MenABCWY doses is 6 months. If a patient receives Penbraya, which includes Trumenba, subsequent Men B dose(s) must include Trumenba since MenB brands are not interchangeable.

**CDPH**  
EZIZ.org IMM-1218 (2/25)

## High-risk Schedule (IMM-1218)

# Updated Job Aids with MenB and Hep B info

**Immunization Recommendations for Adults with HIV<sup>1</sup>**

Vaccines	Recommended Schedules <sup>1,2</sup>	Additional Considerations
COVID-19	1 updated vaccine, regardless of prior vaccine history. See <a href="#">COVID-19 Vaccine Timing Guide</a>	Advanced HIV infection: ≥ 1 updated vaccine(s). Additional doses based on clinical factors <sup>3</sup> .
Hepatitis A (HepA) <sup>4</sup>	Havrix <sup>®</sup> , Vaqta <sup>®</sup> : 2 doses, 6 months apart Twinrix <sup>®</sup> (HepA/HepB): 3 doses 0, 1, and 6 months apart	Check titers ≥ 1 month after series completion. If inadequate immune response, consider revaccination after CD4 ≥ 200 cells/mm <sup>3</sup> .
Hepatitis B (HepB) <sup>5</sup>	Engerix-B <sup>®</sup> , Recombivax HB <sup>®</sup> : 3 doses 0, 1, and 6 months apart Hepilisav-B <sup>®</sup> : 2 doses, 1 month apart Twinrix <sup>®</sup> (HepA/HepB): 3 doses, 0, 1, and 6 months apart	Consider double-dose strategy if using Engerix-B <sup>®</sup> or Recombivax HB <sup>®</sup> . Check titers ≥ 1 month after series completion. If inadequate immune response, consider revaccination after CD4 ≥ 200 cells/mm <sup>3</sup> .
Human papillomavirus (HPV)	Gardasil 9 <sup>®</sup> : 3 doses, 0, 1-2, and 6 months apart for ages 15-45 years	Not routinely recommended for ages 27-45 years but some people with HIV in this age range may benefit. Use shared clinical decision-making.
Influenza	1 dose annually	Live attenuated vaccine is contraindicated.
Measles, mumps, rubella (MMR)	M-M-R <sup>®</sup> II, Priorix <sup>®</sup> : 2 doses, 28 days apart <sup>6</sup>	Contraindicated if CD4 < 200 cells/mm <sup>3</sup> .
Meningococcal A, C, W, Y (MenACWY)	MenQuadfi <sup>®</sup> , Menveo <sup>®</sup> : 2 doses, 2 months apart; booster every 5 years	Meningococcal cases increased among people with HIV 2017-2022; vaccine coverage remains low.
Meningococcal B (MenB)	Bexsero <sup>®</sup> : 2 dose schedule: 0, 6 months. 3 dose schedule: 0, 1-2, and 6 months Trumenba <sup>®</sup> : 2 dose schedule: 0, 6 months. 3 dose schedule: 0, 1-2, and 6 months	Not routinely recommended for all adults with HIV. <sup>7</sup> MenB brands are not interchangeable.
Mpox virus <sup>8</sup>	JYNNEOS <sup>®</sup> : 2 doses, 28 days apart	Can be given intradermally or subcutaneously.
Pneumococcal (PCV15, PCV20, PCV 21, or PPSV23)	Capvaxine <sup>®</sup> (PCV21), Prevnar 20 <sup>®</sup> (PCV20): 1 dose OR Vaxneuvance <sup>®</sup> (PCV15) + Pneumovax 23 <sup>®</sup> (PPSV23): > 2 months apart	Consider delay of PPSV23 until CD4 ≥ 200 cells/mm <sup>3</sup> .
Respiratory Syncytial Virus (RSV)	ABRSVVO <sup>®</sup> , AREXVY <sup>®</sup> , MRESVIA <sup>®</sup> : 1 dose	Recommended for ages ≥ 75 years and ages ≥ 60-74 years with risk factors. Give ABRYSVO at 32 to 36 weeks of pregnancy during September-January. <sup>9</sup>
Tetanus, diphtheria, pertussis (Tdap/Td)	1 dose Tdap (Boostrix <sup>®</sup> , Adacel <sup>®</sup> ), then Td (Tenivac <sup>®</sup> , TDVAX <sup>®</sup> ) OR Tdap booster every 10 years	During each pregnancy, give one dose of Tdap. <sup>10</sup>
Varicella (VAR)	Varivax <sup>®</sup> : 2 doses, 28 days apart <sup>11</sup>	Contraindicated if CD4 < 200 cells/mm <sup>3</sup> .
Zoster (RZV)	Shingrix <sup>®</sup> : 2 doses for ages > 19 years, 2 months apart	Consider delay of Shingrix until CD4 > 200 cells/mm <sup>3</sup> .

CDPH California Department of Public Health | Immunization Branch IMM-1450 (1/25)

## People Living with HIV (IMM-1450)

**Immunization Recommendations for Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM)<sup>1,2</sup>**

Vaccine	Vaccine Options and Schedule	Recommendations and Considerations
Hepatitis A (HepA)	Havrix <sup>®</sup> , Vaqta <sup>®</sup> : 2 doses, 6 months apart Twinrix <sup>®</sup> (combination HepA/HepB): 3 doses, 0, 1, and 6 months apart	Outbreaks & GI syndromes caused by enteric pathogens or common sexually transmitted infections (STIs) can occur among sexual/social networks. For People with HIV (PWH): Check titers > 1 month following HepA series completion.
Hepatitis B (HepB) <sup>3</sup>	Engerix-B <sup>®</sup> , Recombivax HB <sup>®</sup> (if ages ≥ 18 years): 3 doses, 0, 1, and 6 months apart Hepilisav-B <sup>®</sup> (if ages ≥ 18 years): 2 doses, 1 month apart Twinrix <sup>®</sup> (combination HepA/HepB): 3 doses, 0, 1, and 6 months apart	For PWH: Consider double-dose strategy with Engerix-B <sup>®</sup> or Recombivax HB <sup>®</sup> . Check titers > 1 month following HepB series completion.
Human papillomavirus (HPV) <sup>3</sup>	Gardasil 9 <sup>®</sup> : ages 9-14 years: 2 doses, 6-12 months apart ages 15-45 years: 3 doses, 0, 1-2, and 6 months apart	Shared clinical decision-making for ages 27-45 years.
Meningococcal A, C, W, Y conjugate (MenACWY)	MenQuadfi <sup>®</sup> , Menveo <sup>®</sup> : Adolescents: 2 doses (at ages 11-12 years and 16-18 years); 1 dose (if first dose at ages 16-18 years) Adults at increased risk: 1 or 2 doses depending on risk factors.	For PWH: 2 doses, 2 months apart. California Department of Public Health (CDPH) recommends MenACWY for MSM and transgender people who have sex with men (1 dose) due to outbreaks of serogroup C invasive meningococcal disease in the United States.
Meningococcal B (MenB)	Bexsero <sup>®</sup> : 2 doses, 6 months apart Trumenba <sup>®</sup> : 2 doses, 6 months apart	Shared clinical decision-making for ages 16-23 years. If a patient is receiving MenACWY and MenB vaccines at the same visit, MenABCWY (Penbraya <sup>™</sup> ) may be given instead. If a patient receives Penbraya, which includes Trumenba, subsequent Men B dose(s) must include Trumenba, since MenB brands are not interchangeable.
Mpox virus	JYNNEOS <sup>®</sup> : 2 doses, 28 days apart	JYNNEOS <sup>®</sup> can be given intradermally or subcutaneously (SC). If age < 18 years or with history of keloid scars, give SC. Minor Consent for Mpox Treatment.

<sup>1</sup> Comprehensive care for GBMSM includes additional routine immunizations not listed above (see Immunization Schedules I CDC) and a review of both STI and HIV risk and prevention strategies (e.g., doxy-PEP, EPT, HIV PEP/prEP, U=U/TasP).  
<sup>2</sup> Vaccine doses administered ≤ 4 days before the minimum interval or age are considered valid. There is no maximum interval between vaccine doses. See Recommended and minimum ages and intervals between vaccine doses I CDC.  
<sup>3</sup> Adolescents age ≥ 12 years can seek sexual health services without parental consent. See California Minor Consent and Confidentiality Laws.  
California Department of Public Health, Immunization Branch IMM-1483 (1/25)

## Gay, Bisexual, and MSM (IMM-1483)

**Immunization Recommendations for Sexually Active People<sup>1,2</sup>**

Vaccine	Vaccine Options and Schedule	Recommendations and Considerations <sup>1-3</sup>
Hepatitis A (HepA)	Havrix <sup>®</sup> , Vaqta <sup>®</sup> : 2 doses, 6 months apart Twinrix <sup>®</sup> (combination HepA/HepB): 3 doses, 0, 1, and 6 months apart	Adolescents not vaccinated as young children Adults with risk factors, <sup>4</sup> including: - Men who have sex with men (MSM) <sup>2,5</sup> - People with HIV (PWH) <sup>6</sup> - People who use drugs - People experiencing homelessness
Hepatitis B (HepB)	Hepilisav-B <sup>®</sup> (if ages ≥ 18 years): 2 doses, 1 month apart Engerix-B <sup>®</sup> (if ages ≥ 18 years), Recombivax HB <sup>®</sup> : 3 doses, 0, 1, and 6 months apart Twinrix <sup>®</sup> (combination HepA/HepB): 3 doses, 0, 1, and 6 months apart	Adolescents not vaccinated as young children Adults ages 19-59 years Adults ages ≥ 60 years with risk factors, <sup>4</sup> including: - MSM <sup>5</sup> - PWH <sup>6</sup> - People who use drugs - People with sexual exposure risk - People who are incarcerated
Human papillomavirus (HPV)	Gardasil 9 <sup>®</sup> : ages 9-14 years: 2 doses, 6-12 months apart ages 15-45 years: 3 doses, 0, 1-2, and 6 months apart	Adolescents and young adults, starting at ages 11-12 years through age 26 years Adults ages 27-45 years, based on shared clinical decision-making
Meningococcal A, C, W, Y conjugate (MenACWY)	MenQuadfi <sup>®</sup> , Menveo <sup>®</sup> : Adolescents: 2 doses (at ages 11-12 years and 16-18 years); 1 dose (if first dose at ages 16-18 years) Adults at increased risk: 1 or 2 doses depending on risk factors.	Adolescents, starting at ages 11-12 years Adults with risk factors, <sup>4</sup> including: - PWH (2 doses, 2 months apart) - MSM <sup>5</sup> (1 dose) - Transgender adults who have sex with men <sup>6</sup> (1 dose)
Meningococcal B (MenB)	Bexsero <sup>®</sup> : 2 doses, 6 months apart Trumenba <sup>®</sup> : 2 doses, 6 months apart	Adolescents and young adults ages 16-23 years, based on shared clinical decision-making
Mpox virus <sup>8</sup>	JYNNEOS <sup>®</sup> : 2 doses, 28 days apart	Adults vulnerable to or seeking added protection. If < 18 years, see Minor Consent for Mpox Treatment.

California Department of Public Health | Immunization Branch IMM-1484 (1/25)

## Sexually Active People (IMM-1484)


# Vaccines for Children

Christina Sapad, CDPH

# 2025 VFC Recertification

- Recertification is due **Friday, February 14, 2025!**
- 3,342 active VFC providers (as of 2/6/25)
  - 1,900 have completed Recertification
  - 198 have E-signature requested
  - 537 are In Progress

Recertifications by Status





# Recertification Tips

- The myCAvax Recertification form is validating EZIZ lesson completion based on information from the EZIZ Training User ID. If your EZIZ training is not being validated:
  - On your EZIZ Learning History Page, click on “Edit Profile” to update your training account information to match your name and email address in your myCAvax account.
  - If you must update your name in your myCAvax account, please contact the Provider Call Center at [mycavax.HD@cdph.ca.gov](mailto:mycavax.HD@cdph.ca.gov) or call (833) 502-1245.
  - After updating your EZIZ training account information, go back to the Recertification form, Key Practice Staff page, and click on “Manage Role.” Click “Submit” on the Manage Role window, which will trigger the training verification process again.
- If your EZIZ Username is not displaying on the “Key Practice Staff” page of the Recertification Form, click on “Manage Role”. From there, you can add your EZIZ username.

**Step 2 - Key Practice Staff**

In order to proceed, you must have at least the Provider of Record, Primary Vaccine Coordinator, Backup Vaccine Coordinator, and Provider of Record Designee information below. These staff members should be those who manage child patients in the VFC program. Medical Licenses will be validated to ensure active status of license.

Organization Vaccine Coordinator is an optional role and is subject to CDPH approval. Review the job aid(s) for [Organization Vaccine Coordinator roles and responsibilities](#) before assigning anyone to this role.

**Key Practice Staff must have their EZIZ program training completed. Please direct any staff members who have not completed the training to the following link: [EZIZ training](#).**

Please Note: Only enter business or public information (no personal emails, phone numbers, or addresses)

**Key Practice Staff**  
Staff members who are responsible for managing the location

Role	Name	Title	Speciality	Clinic Title	Email	Phone Number	NPI ID	License No.	EZIZ Username	Training Complete	Actions
Provider of Record	[Redacted]	NP - Nurse Practitioner		Other	[Redacted]					✗	<a href="#">Manage Role</a>
Primary Vaccine Coordinator	[Redacted]	NP - Nurse Practitioner		Other	[Redacted]					✗	<a href="#">Manage Role</a>
Backup Vaccine Coordinator	[Redacted]			Medical Assistant	[Redacted]					✗	<a href="#">Manage Role</a>
Provider of Record Designee	[Redacted]		Other	Other	[Redacted]				[Redacted]	✓	<a href="#">Manage Role</a>

# VFC Provider Satisfaction Survey

- A link to complete and submit the Provider Satisfaction Survey will appear after submitting your Recertification for e-signature.
- If you haven't had a chance to complete the survey, you can access it here: [VFC Provider Satisfaction Survey](#).
- Your input is greatly valued and will guide enhancement to our program, educational resources, staff training, and systems.



California Vaccines  
for Children Program

We appreciate your participation in Vaccines for Children and want to do our best to support you.

Your opinion is important for the continued success of California's VFC Program; we need to hear from you. Please take a few minutes to answer our short VFC Program Satisfaction Survey. This survey is confidential and should take about 5 minutes to complete.

Thank you.



# Recertification Resources

Micro-video and Job Aid via myCAvax Knowledge Center: [Recertifying Vaccines for Children \(VFC\), Vaccines for Adults \(VFA\) and LHD 317 Program Locations](#)

## California Vaccines for Children (VFC) Program 2025 Program Participation Requirements

State of California—Health and Human Services Agency  
California Department of Public Health

### VACCINES FOR CHILDREN (VFC) PROGRAM

**VACCINES FOR CHILDREN PROGRAM PROVIDER AGREEMENT**

**PROVIDER AGREEMENT**

**Instructions:** The official VFC-registered health care provider signing the agreement must be a provider authorized to administer pediatric vaccines\* under state law, who will also be held accountable for compliance by the entire organization and its VFC providers with the responsible conditions outlined in the provider enrollment agreement. The individual listed here must sign the provider agreement.

\*Note: For the purposes of the VFC program, the term "vaccine" is defined as any FDA-authorized or ACIP-recommended product for which ACIP approves a VFC resolution for inclusion in the VFC program.

To receive publicly funded vaccines at no cost, I agree to the following conditions on behalf of myself and my practitioners, nurses, and others associated with the health care facility of which I am the medical director or administrator or equivalent:

- I will annually submit a provider profile representing populations served by my practice/facility. I will more frequently if 1) the number of children served changes or 2) the status of the facility changes on a calendar year.
- I will screen patients and document eligibility status at each immunization encounter for VFC (federally or state vaccine-eligible) and administer VFC-purchased vaccine by such category only to children 18 years of age or younger who meet one or more of the following categories:
  - Federally Vaccine-eligible Children (VFC eligible)
    - Are an American Indian or Alaska Native;
    - Are enrolled in Medicaid;
    - Have no health insurance;
    - Are underinsured: A child who has health insurance, but the coverage does not include a child whose insurance covers only selected vaccines (VFC-eligible for non-covered vaccines). Underinsured children are eligible to receive VFC vaccine only through a Federally Qualified Health Center (FQHC), or Rural Health Clinic (RHC) or under an approved deputization agreement.
  - State Vaccine-eligible Children
    - In addition, to the extent that my state designates additional categories of children as "state vaccine-eligible," I will screen for such eligibility as listed in the addendum to this agreement and will administer state-funded doses (including 317 funded doses) to such children.

Children aged 0 through 18 years that do not meet one or more of the federal vaccine eligibility categories (VFC-eligible), are **not** eligible to receive VFC-purchased vaccine.
- For the vaccines identified and agreed upon in the provider profile, I will comply with immunization dosages, and contraindications that are established by the Advisory Committee on Immunization (ACIP) and included in the VFC program unless:
  - In the provider's medical judgment, and in accordance with accepted medical practice, the provider deems such compliance to be medically inappropriate for the child;
  - The particular requirements contradict state law, including laws pertaining to religious accommodations and exemptions.

California Department of Public Health, Immunization Branch

## California Vaccines for Children (VFC) Program Provider Agreement Addendum

I, on behalf of myself  
Maintenance Organization,  
which I am the physician,  
listed below.

### 1. Provider Profile

- Designate the assume responsibility.
- Designate the implementing organization.
- Immediately of Record or the Provider.
- Immediately require additional information.

### 2. Vaccine Management

- Maintain a calendar that includes monitoring requirements.
- Review and update designated vaccine information.
- Designate a staff member to plan annually.
- Follow emergency procedures.
- Store the vaccine information.
- For practices with mobile units, the mobile unit information.

### 3. Training

- Anyone acting on behalf of the Organization when hired or recommended.
- Any clinician recommended for the program.
- All staff who are recommended for the program.
- All staff and students who are recommended for the program.

EZIZ.org

CDPH VFC California Vaccines for Children Program

## 2025 Recertification Process

### 1. ENSURE YOUR ACCOUNT IS IN GOOD STANDING

Provider accounts that are SUSPENDED due to Mandatory Reporting are not eligible for the Recertification form.

### 2. GATHER INFORMATION ON THE RECERTIFICATION PROCESS

Use the 2025 Recertification Worksheet to gather information needed ahead of time to complete the process.

### 3. COMPLETE REQUIRED EZIZ LESSONS

Complete required EZIZ lessons before accessing 2025 updated this year. To receive credit for the annual training, you must complete the lessons before the Recertification launches.

### 4. ACCESS THE RECERTIFICATION FORM

Login to your myCAvax account and click on the "Submit My Profile" link.

### 5. VERIFY AND UPDATE YOUR PRACTICE INFORMATION

Verify and update information about your practice, including practice staff, patient estimates, vaccine storage and delivery, and who will be administering immunizations. Preview all information before submitting.

### 6. SUBMIT FOR E-SIGNATURE FOR PROVIDER OF AGREEMENT AND PROVIDER AGREEMENT ADDENDUM

The Provider of Record must review and electronically sign the 2025 "Provider Agreement" and "Provider Agreement Addendum". The Provider of Record must review and electronically sign the 2025 "Provider Agreement" and "Provider Agreement Addendum". The Provider of Record must review and electronically sign the 2025 "Provider Agreement" and "Provider Agreement Addendum".

## California Vaccines for Children (VFC) Program RECERTIFICATION WORKSHEET

Use this worksheet to gather information needed ahead of time to complete the process on myCAvax.cdpb.ca.gov.

DO NOT SUBMIT THIS WORKSHEET TO THE VFC PROGRAM.

Step 1—Location Information/Shipping		
Location Name	PIN	
Practice Information/Shipping Address (No P.O. Box)	City	
Shipping Address, Part 2	County	
Tax ID/Employer Identification Number (EIN)	National Provider Identifier (NPI)	Phone
MEDI-CAL Provider? <input type="checkbox"/> Yes <input type="checkbox"/> No	Is this a mobile facility, or does this facility have mobile units? <input type="checkbox"/> Yes <input type="checkbox"/> No	
DELIVERY: Check all days and times you may receive vaccine. If closed during lunch hour, please specify.		
<input type="checkbox"/> Monday	From:	To: (Closed for)
<input type="checkbox"/> Tuesday	From:	To: (Closed for)
<input type="checkbox"/> Wednesday	From:	To: (Closed for)
<input type="checkbox"/> Thursday	From:	To: (Closed for)
<input type="checkbox"/> Friday	From:	To: (Closed for)

Step 2—Key Practice Staff					
Role/Responsibility	Name	Title (MD, DO, NP, PA, PharmD)	Specialty/Clinic Title	National Provider ID	Medi Licen #
Provider of Record			Specialty: _____ Clinic Title: _____		
Vaccine Coordinator			Specialty: _____ Clinic Title: _____		
Backup Vaccine Coordinator			Specialty: _____ Clinic Title: _____		
Provider of Record Designee			Specialty: _____ Clinic Title: _____		

California Department of Public Health Immunization Branch

IM96-1277 (1/2/24)

CDPH VFC VFA LHD 317

## Recertification Frequently Asked Questions

Memory usage: 198 MB

### Contents

Know what you are looking for? Use the following links to easily locate the answer.

- Managing EZIZ Training Account
- EZIZ Lessons
  - Learning History Page
- Recertification Form
  - Step 1: Provider Location Information
  - Step 2: Key Practice Staff
  - Step 3: Vaccine Storage Units
  - Step 4: Provider Population
  - Step 5: Health Care Providers with Prescription Writing Privileges
  - Step 6: My Turn Vaccine Locator (VFC Providers)
  - Step 7: Review Recertification Information
  - E-Signature
- After Recertification

### Managing EZIZ Training Account

**Q: What information on my EZIZ Training Account do I need to make sure is correct so that I can get Recertification credit for taking the lessons?**  
A: Since myCAvax is connected to validate EZIZ training lessons, the name (first and last) and email listed on myCAvax must match the name and email on the EZIZ training account used to complete the required lessons. Each key practice staff must have a unique email and EZIZ user ID.

**Q: How do I update the email address for my EZIZ training account?**  
A: Use the "Edit Profile" link in the blue My Account section in the upper right-hand corner of the page.

**Q: Are the required lessons for Recertification now on myCAvax?**  
A: The EZIZ lessons are still located on the EZIZ.org website. The actual Recertification Form is on your myCAvax program location account.

**Q: What information related to my account can be updated?**  
A: Using the "Edit Profile" link in the blue My Account section in the upper right-hand corner of the page, the following information on file for your account may be updated: First Name, Last Name, Email, Account Password and PINs your account is currently linked to.

California Department of Public Health, Immunization Branch

Page 1 of 13

IMM-1245 (12/24)

# 2025 – 2026 VFC Flu Vaccine Pre-Book Now Closed




## VFC Review of Pre-Book Requests

- The due date to submit VFC Flu Pre-Book was February 3. The California VFC Program will now review 2025-2026 Flu Pre-Book requests to determine how many doses of each product to pre-book through CDC.

## Final Pre-Book Approval Confirmation (early 2025)

- Once the VFC Program's pre-booked doses are approved by the CDC, VFC will notify providers of their approved pre-book amounts.
- Final approved pre-book amounts may or may not be different from what your practice had pre-booked, depending on product availability approved by the CDC.
- No changes can be accommodated once approved and final. Pre-booked doses will constitute your vaccine supply for the entire season. Remember, you are responsible for ordering your confirmed allocation.
- For providers who did not pre-book, VFC will allocate doses and brands for ordering based on available products. Please ensure that your EHR or billing systems are ready to accommodate any flu brand.

# How to View Your Submitted 2025 – 2026 VFC Flu Pre-Book



1. From the Prebook landing page, providers can click the **View Prebook** hyperlink corresponding to the appropriate Prebook order to access the **Prebook Order** page.

## Once VFC approves the Pre-Book Amounts (early 2025):


1. On the **Prebook Order** page, **Provider Allocation** details can be found in the **Related** tab. Providers can click the appropriate **Provider Allocation Number** hyperlink to access the **Provider Allocations** page.
2. In the **Details** tab on the **Provider Allocations** page, providers will find the approved pre-book amount in the **Total to be Allocated by CDPH** field. (under the **Allocation Details** page section)

# Vaccines for Adults


Nisha Gandhi, CDPH

# 2025 VFA Recertification Status

- Due Date: **Friday, February 14, 2025**
- 497 active VFC providers
  - 302 have completed Recertification
  - 45 have E-signature requested
  - 47 are In Progress



# VFA Recertification Documents






State of California—Health and Human Services Agency  
California Department of Public Health

TOMÁS J. ARAGÓN, M.D., Dr.P.H.  
Director and State Public Health Officer

Vaccines for Adults & Local Health Department 317 Programs  
**RECERTIFICATION WORKSHEET**

Use this worksheet to gather information needed ahead of time to complete the online VFA or LHD 317 Recertification Form on [myCAvax.cdph.ca.gov](http://myCAvax.cdph.ca.gov).

**DO NOT SUBMIT THIS WORKSHEET TO THE VFA or LHD 317 PROGRAMS.**

December X

TO: C

FROM: R  
C  
D

SUBJECT: 2

BACKGROU



Thank you for ensures acci adults. Annu publicly purc Recertificati account term

Through rec requirements eligible and p Program the and valid Ca

SUBMIT 202

The 2025 V your comple will be valid t

(51)

California Vaccines for Children

## 2025 Recertificati

**1** | ENSUR  
Provide the Rec

**2** | GATHE  
Use the process

**3** | COMPL  
Comple updated Recertif

**4** | ACCESS  
Login to

**5** | VERIFY  
Verify a practice who wil

**6** | SUBMIT  
AGREE  
The Pre in the 21 DocuSig Agree

California Vaccines for Adults (VFA) Program

### 2025 Program Participation Requirements at a Glance

Requirement	Summary	Resources/Job Aids
Vaccine Management Plan	<p>Maintain a current and completed vaccine management plan (VMP) for routine and emergency situations that includes practice-specific, vaccine-management guidelines and protocols, names of staff with temperature monitoring responsibilities, and completion dates of required EZIZ lessons for key practice staff.</p> <p>Review and update the VMP at least annually, when program requirements change, and when staff with designated vaccine-management responsibilities change.</p> <p>Designate a staff member responsible for updating the practice's VMP.</p> <p>Staff with assigned vaccine-management responsibilities must review, sign, and date the VMP annually and each time it is updated.</p> <p>Follow emergency guidelines to prepare for, respond to, and recover from any vaccine-related emergencies.</p> <p>Store the VMP in a location easily accessible by staff, ideally near the vaccine storage units.</p> <p>Practices using mobile units to administer VFA-supplied vaccines must maintain a current and complete Mobile Unit VMP and keep it in the mobile unit.</p>	<p><a href="#">Vaccine Management Plan (IMM-1272)</a></p> <p><a href="#">Provider Operations Manual (IMM-1248) Chapter 3</a></p> <p><a href="#">Mobile Unit Vaccine Management Plan (IMM-1276)</a></p>
Key Practice Staff <i>Updated!</i>	<p>Designate and maintain key practice staff in the practice's profile on myCAvax. Immediately report in myCAvax any changes to key practice staff roles (Vaccine Coordinator or Backup, Provider of Record or Designee); any changes to the terms of the VFA "Provider Agreement" and the "VFA Provider Agreement Addendum" and is ultimately accountable for the practice's compliance. Must be a licensed MD, DO, NP, PA, pharmacist, or a Certified Nurse Midwife with prescription-writing privileges in California.</p> <p><b>Provider of Record (POR):</b> The on-site physician-in-chief, medical director, or equivalent who signs and agrees to the terms of the VFA "Provider Agreement" and the "VFA Provider Agreement Addendum" and is ultimately accountable for the practice's compliance. Must be a licensed MD, DO, NP, PA, pharmacist, or a Certified Nurse Midwife with prescription-writing privileges in California.</p> <p><b>Provider of Record Designee:</b> The on-site person who is authorized to sign VFA Program documents and assumes responsibility for VFA-related matters in the absence of the Provider of Record.</p> <p><b>Vaccine Coordinator:</b> An on-site employee who is fully trained and responsible for implementing and overseeing the practice's vaccine management plan.</p> <p><b>Backup Vaccine Coordinator:</b> An on-site employee fully trained in the practice's vaccine management activities and fulfills the responsibilities of the Vaccine Coordinator in his/her absence.</p>	<p><a href="#">Vaccine Coordinator Roles &amp; Responsibilities (IMM-968)</a></p> <p><a href="#">VFA Key Practice Staff Change Request Form (IMM-1523)</a></p> <p><a href="#">VFA Provider Agreement (IMM-1514)</a></p> <p><a href="#">VFA Provider Agreement Addendum</a></p>

- [VFA 2025 Provider Agreement](#)
- [VFA/LHD 317 2025 Provider Agreement Addendum](#)
- [VFA Recertification Program Letter](#)
- [2025 Recertification Process](#)
- [VFA/LHD 317 Recertification Worksheet](#)
- [2025 VFA Program Requirements At a Glance](#)
- [Recertification FAQs](#)
- [Recertification Demo \(myCAvax login required\)](#)

Immunization Branch

48





# VFA Ordering Window Extended!

- VFA Q1 Ordering Period : January 23 – February 14, 2025
  - As of February 6, 233 VFA orders submitted
- Reminder: VFA **does not** offer routine supplemental orders
- Q1 Ordering Policy:
  - Vaccine dose requests for PCV 20 and Shingrix will be capped at 40 doses
  - VFA sites can **order up to 20 doses of either** Abrysvo or Arexvy vaccine. Clinics can **only** select one brand of RSV vaccine to order.
    - Vaccine requests will be approved based on availability and ordering will close once our annual supply has been depleted.
    - If the preferred vaccine brand is unavailable, a CDPH rep will reach out to the provider about proceeding with the alternative brand.
  - Caps for all other routine vaccines will remain the same



- Have questions or need assistance with ordering?

[ProviderCallCenter@cdph.ca.gov](mailto:ProviderCallCenter@cdph.ca.gov)


(833) 502 – 1245

# Vaccine Management

Josh Pocus, My Turn, and Dan Conway, myCAvax

# What's New in My Turn? – Release 56

New updates for Patients, Clinic Managers, and Vaccine Administrators launched on **Wednesday, January 22, 2025!**



## Release Highlights

My Turn Public

- ✓ The 'Pharmaca' pharmacy link will be removed from the 'Vaccine Locator' page
- ✓ A 'Note,' vaccination location tags, a legend, and an enhanced vaccine locator card will be added, along with a pop-up note which direct patients to the 'Let's get started' page on the 'Vaccine Locator' page
- ✓ A new 'What type of insurance does the patient have?' question will be added, along with updated and reordered fields in the 'Health Insurance' section on the 'Patient Information' page while scheduling an appointment on the My Turn portal



## Release Highlights

My Turn Clinic

- ✓ An error message will appear when a duplicate clinic name is detected during the clinic creation flow
- ✓ An error message will appear below the 'Internal Clinic Name' and 'Public Clinic Name' fields if the clinic name exceeds 80 characters on the clinic creation flow
- ✓ An error message will appear below the 'Start Date' field if a Traditional Mpox vaccine, Dose 1 and Dose 2 appointment with a less than 28-day interval is detected during the Inline bulk upload flow
- ✓ Updated Mpox and Pneumonia (pneumococcal) adults vaccine values will appear
- ✓ A new 'Type of Insurance' column will be added, and health insurance-related fields will be updated and reordered on the Inline / CSV bulk upload flow
- ✓ The warning banner stating that the vaccine contains Thimerosal and is not recommended for pregnant individuals appears for all Afluria, Flucelvax, and Fluzone multi-dose vaccines on the 'Vaccine Inventory' page
- ✓ A new 'What type of insurance does the patient have?' question will be added, and fields will be reordered and updated in the 'Health Insurance' section on the 'Patient Information' page while scheduling an appointment on the Walk-in and VA flows
- ✓ Clicking the 'X' icon on the 'Help Desk Virtual Assistant' screen will end the chat and notify the live chat agent that the provider / end user has left
- ✓ The Help Desk FAQ Virtual Assistant flow gets restructured

# Vaccine Locator – Opt-In today!

Program Locations that have Opted-In:



Please take some time to opt-in, **preferably right now!** We want patients to be able to find you.

We want to congratulate **Los Angeles County** for their participation and being the top county with **171 Locations** opted-in!

Data as of 2/6/25



**Thank you for opting into the Vaccine Locator. By doing so, you are ensuring that patients can easily find your locations. Your participation is invaluable in helping patients access the care they need.**

- 101 FAMILY MEDICAL GROUP
- 3C Community Clinic
- 986 Pharmacy 8001 Inc
- AFSHIN SHAWN ADHAMI
- A. Shawn Adhami MD - Morelia M.C.
- Family Care Associates
- ABC CHILDREN'S CLINIC INC
- ABC Pediatrics Inc
- ABCUSD Immunization Clinic
- Crenshaw Family Medical Group
- Acacia Family MG - Prunedale
- Acacia Family MG - Salinas
- Access Support Network
- ACTIVE HEALTHCARE MEDICAL GROUP
- Adelanto Medical Clinic
- ABC PEDIATRICS MEDICAL GROUP INC
- Advanced Family Care Medical Group
- AHMO-Parlier Newmark
- AHMO-Orange Cove
- AHMO-Reedley Children's
- AHCC-Cal City
- AHCC TEHACHAPI
- AHCC Mojave
- AHMO-Wasco
- Adventist Health Community Care
- AHMO-Hanford-Residency
- St Helena Konocti Wellness Center
- ADVENTIST HEALTH MIDDLETOWN
- UKIAH VALLEY RURAL HEALTH CENTER AD
- Adventist Health Physicians Network
- Redwood Medical Clinic
- AHUV FORT BRAGG RHC
- AHUV- RHC Pediatrics
- CORNING RURAL HEALTH CLINIC
- Roseville Immunization Clinic
- Sacramento Immunization Clinic
- Sutter Health PAMF Fremont Clinic
- Sutter Medical Foundation - Davis
- SMF-Eik Grove Medical Campus
- SEBMF - Castro Valley
- SVMF - FP Yuba City
- Sutter Medical Center Sacramento
- Alta Bates Summit Medical Center
- Sutter Santa Rosa Regional Hospital
- Sutter Coast Hospital
- Sutter Lakeside Hospital and Clinic
- SPMF CAL IM PEDS
- SPMF Castro
- PAMF San Carlos Clinic
- Sutter Health VNG 4th Floor
- SMF Peds Vallejo
- SMF Peds Vacaville
- Sutter Ocean Ave SF
- Sutter PMSZ PAMF Pediatrics Dept.
- SPMF Rhode Island
- SMF Downtown Sacramento Pediatrics
- PAMF - Scotts Valley
- PAMF-Westside
- SMF Amador Jackson Pediatrics
- SMF Davis Peds
- Olympic
- Ace Pediatrics
- Symba Center
- SYMONETT FAMILY MEDICAL CENTER
- Sea View Pediatrics- Laguna Hills
- Pediatric and Adult Medicine
- SOCPA- Lake Forest
- Pomona Pediatrics
- Premier Pediatrics
- SOCPA- San Clemente
- SOCPA- Rancho Santa Margarita
- Children's Medical Clinic

# In Case You Missed It! – My Turn Webinar Recap

- The My Turn team hosted a “My Turn Benefits” session on Tuesday, January 14, 2025
- ~100 participants joined the session – **THANK YOU!**
- Resources available
  - [My Turn Vaccine Administration System on EZIZ](#)
    - “My Turn Benefits” session [recording](#) and [slides](#)
    - [My Turn Onboarding Guide](#)
    - [Enrolling in My Turn Quick Sheet](#)
    - Support Information

The screenshot shows the My Turn Vaccine Administration System website. At the top, there is a search bar with the text "ENHANCED BY Google" and a search icon. Below the search bar is the tagline "A one-stop shop for immunization training and resources." The main navigation menu includes links for Home, Vaccine Programs, Vaccine Management, Storage Units, Temperature Monitoring, Training & Webinars, Clinic Resources, and Patient Resources. The "Contact VFC" section provides contact information: Phone: (877) 243-8832, Hours: Mon-Thurs, 9AM-4:30PM; Friday, 9AM-4PM, and options to send an email or fax: (877) 329-9832. There are also links for VFC Field Representatives, Find VFC providers, Sign up for EZIZ emails, and Frequently Asked Questions. The main content area is titled "Vaccine Administration System" and "My Turn". It describes the system as an all-in-one application for vaccine eligibility, appointment scheduling, and reporting. It lists steps to enroll, distinguishing between users who do not have a myCAvax account and those who do. Enrollment resources include a My Turn Onboarding Guide, a quick sheet, and a new clinic flyer. Contact information for the Provider Call Center is also provided.

# myCAvax Release Roadmap

**Past Release**  
January 8, 2025 (R53)

## Release 53

### VFC

- ✓ VFC Flu Prebook

### VFC/VFA/317

- ✓ Orders will be sorted by Submitted Date on CDPH Order Review
- ✓ Storage Unit Changes will no longer create holds
- ✓ Self-service provider agreements updated

### All Programs

- ✓ View Shipments at program location level
- ✓ Holds will be automatically closed with a unit is marked 'No Longer in Use'
- ✓ Filter out provider inventories that are not being used

**Current Release**  
February 5, 2024 (R54)

## Release 54

### VFC

- ✓ Allocations for VFC Flu and the ability to create first orders based on provider prebook orders
- ✓ Enrollment Provider Agreement updated

### VFC/VFA/317

- ✓ Providers will be notified when their order is pending
- ✓ Messaging will be added when products are not available for ordering
- ✓ CDPH will have a shortened create order form and providers will be notified when orders are created by CDPH
- ✓ Site Visit enhancements

### All Programs

- ✓ Only one open excursion will be allowed at a time and excursions will be able to be cancelled
- ✓ Provider Inventories will be enhanced to include a new page layout and balance on the inventory summaries

**Next Release**  
March 5, 2024 (R55)

## Release 55

### VFC

- ✓ Display CAIR dose administration information on ordering page (provider) and order review page (CSR)
- ✓ Give providers access to both myCAvax Dashboard and Flu & COVID Orders Dashboard

### VFC/VFA/317

- ✓ Provider agreement for Designee staff management requests will send one agreement to Designee & POR to sign

### All Programs

- ✓ Print account and program location information from program location page
- ✓ Enhance trash can functionality on provider ordering form
- ✓ Include order cost on shipment records
- ✓ Enforce restriction so that only expired doses can be returned

# What's Next in myCAvax? – Release 54

New updates for providers will launch on Wednesday, **February 5, 2025!**

## Release Highlights



Providers

### Provider Allocation Page

- ✓ A new 'Provider Allocation' page is created to view provider allocation details.

### myCAvax Login Page Instructions

- ✓ Updated text with clear instructions for resetting the password on the myCAvax Login page.

### Mapped POR in DocuSign

- ✓ The Provider of Record (POR) is visible in updated DocuSign documents in the VFC enrollment flow.

### Site Visit Fields Updated

- ✓ 'Supervisor' and 'Shadow' fields are updated on the Site Visit page.

### Rejection Email Update

- ✓ The 'Rejected' status reason is visible in the email when a Staff Management Request is rejected.

### Staff Management Job Aid

- ✓ The 'Managing Staff in Program Location' job aid link is updated on the Manage Staff page.

### Inventory Summary Update

- ✓ Updated columns in the 'Inventory Summary' section, now moved to the 'Details' tab on the Provider Inventory page.

### Storage Unit Fields

- ✓ New fields 'Type' and 'Unit Grade' are added in the 'Details' tab on the Storage Unit page.



# What's Next in myCAvax? – Release 54 (Cont.)

New updates for providers will launch on Wednesday, **February 5, 2025!**

## Release Highlights



### Order Email Updates

- ✓ A new email is sent when a vaccine order request is created internally.
- ✓ An order status email is sent when the status changes to 'Corrections Needed,' 'Approval,' 'Expired,' or 'Rejected.'
- ✓ A pending status email provides an update on the order status and reason.

### Error Messages for Ordering

- ✓ Three new error messages are visible when products are unavailable for ordering.

### Order Request Columns

- ✓ Two new columns, 'Order Size Reason' and 'Please Specify "Other",' are visible during 'Draft' and 'Correction Needed' order requests.

### Excursions Page Updates

- ✓ Excursion draft can be saved with minimal information.
- ✓ A warning banner appears if an excursion draft already exists for a program location.
- ✓ If multiple draft excursions exist for a location, the oldest ones are marked as 'Cancelled' and removed from Excursions page.

### Recertification & Enrollment

- ✓ Updated the 'Add Ultra Freezer' button name.
- ✓ Fields are updated for adding Key Practice Staff via the 'Add Contact' hyperlink and managing roles via the 'Manage Role' hyperlink during recertification.

# R54 Enhancement: Updated Password Reset Guidance

**myCAVax**  
California Vaccine Management System

## Password Reset

To reset your password, we'll need your username. Please use the following format:  
youremail@yourdomain.com.mycavax. We'll send password reset instructions to the email address associated with your account.

**Please note:** If you do not receive an email or have not logged in for 90 days or more, please contact the Provider Call Center for assistance at [mycavax.hd@cdph.ca.gov](mailto:mycavax.hd@cdph.ca.gov) or call (833) 502-1245, Monday-Friday 8 am-5 pm.

**Reset Password**

[Changed your mind? Back to Login](#)

- The text on the password reset page has been updated to provide more clear instructions on the password reset process.

## Updated Text:

To reset your password, we'll need your username. Please use the following format as an example: [youremail@yourdomain.com.mycavax](mailto:youremail@yourdomain.com.mycavax).

We'll send password reset instructions to the email address associated with your account.

Please note: If you do not receive an email or have not logged in for 90 days or more, please contact the Provider Call Center for assistance at [myCAVax.hd@cdph.ca.gov](mailto:myCAVax.hd@cdph.ca.gov) or call (833) 502-1245, Monday – Friday 8:00 am – 5:00 pm.

# R54 Enhancement: Display Provider Allocations while on the VFC Order Form

**\* Program Location**

Reshma's Unicorn Island - Vaccines for Children

**Select Location, Provide Inventory and Doses Administered for Vaccines listed.**

- Ensure the current VFC inventory in your vaccine storage units matches the On-hand Inventory you enter.
- Your VFC Doses Administered inventory must match the immunization registry (CAIR/Healthy Futures).
- View the provider inventory link below to account for every dose your location has received. If your calculated provider inventory does not match, please ensure that you have reported all transfers, waste events, and returns prior to this order request.

Next Order Due Date (approximate) ⓘ	Provider Inventory ⓘ	Allocations ⓘ	Practice Volume & Order Frequency ⓘ
November 13, 2024	<a href="#">View Provider Inventory</a>	<a href="#">View Allocation Details</a>	High (monthly)

Program Location > Reshma's Unicorn Island - Vaccines for Children

**Provider Allocations**

35 Items. Sorted by Total to be Allocated. Filtered by Display Provider Allocations

Product Name	Total to be Allocated ↑	Allocation Received to Date	Available to Order
1 FluLaval 2025-2026 Single-Dose Syringes - 10 Per ...	100	50	50
2 Flucelvax 2024-2025 Single Dose Syringes - 10 Per...	200	0	0
3 FluMist 2024-2025 Intranasal Spray- 10 Per Box	200	0	0
4 Fluzone (2023-2024) Single Dose Syringes - 10 Per...	200	50	50
5 Fluzone 2024-2025 Single Dose Syringes - 10 Per ...	304	0	0
6 FluLaval 2024-2025 Single Dose Syringes - 10 Per ...	611	0	0
7 VFC Shared Flu	3000	1791	1491

- While on the VFC order form, providers can view their open allocation details by clicking the 'View Allocation Details' hyperlink.
- The allocations table will show providers how much they will be allocated, how much they've been allocated, and what they can order of those products.

# R54 Enhancement: New Messaging for Unavailable Vaccine Products

While placing a vaccine order, providers will be notified of products that are unavailable to order.

- When a product is unavailable for ordering, an orange message will appear reading, "Unavailable for ordering. Inventory and Doses Administered can still be reported."

Vaccine product	*Quantity	Lot number ⓘ	Expiration Date / Beyond use date ⓘ	+ ⓘ	*Qty since last order ⓘ	Estimated Provider inventory ⓘ	Variance ⓘ	Recommended Order size ⓘ	*Doses requested	Clear Row
DTaP/IPV Quadracel Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/>	+	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	0	Clear Row
Quadracel Single Dose Vials (2025 expiry)- 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/>	+	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	0	Clear Row
Quadracel Single Dose Vials (2024 expiry)- 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/>	+	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	0	Clear Row

Unavailable for ordering. Inventory and Doses Administered can still be reported.

# R54 Enhancement: Ordering Within Allocation

- For products that have allocations, providers will not be able to request more doses than what CDPH has currently made available to them.

Vaccine product	*Quantity	Lot number	Expiration Date / Beyond use date	*Qty since last order	Estimated Provider inventory	Variance	Recommended Order size	*Doses requested
<p> Your doses requested exceeds your remaining allocation. You can only order up to your allocation of 50 doses.</p>								
<p> Your order is outside of the recommended order size and may be adjusted based on the information provided.</p>								
Fluzone (2023-2024) Single Dose Syringes - 10 Per Box	<input type="text" value="0"/>	<input type="text"/>	<input type="text"/> +	<input type="text" value="0"/>	<input type="text" value="0"/>	0	<input type="text" value="0"/>	<input type="text" value="60"/>

# R54 Enhancement: Enhancements to Orders in Draft and Corrections Needed Status


- Orders in 'Draft' and 'Corrections Needed' status will have the same validations and messaging apply as when creating an order for the first time.

Vaccine product	*Quantity	Lot number	Expiration Date / Beyond use date	*Qty since last order	Estimated inventory	Variance	Recommended Order size	*Doses requested	Order size reason
Flucelvax 2024-2025 Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text" value="0"/>		<input type="text"/>	<input type="text" value="0"/>	<input type="text" value="-Select-"/>
Unavailable for ordering; this program does not have an allocation for this product.									
FluLaval 2024-2025 Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text" value="0"/>		<input type="text"/>	<input type="text" value="0"/>	<input type="text" value="-Select-"/>

Adacel Single Dose Syringes - 5 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text"/>	<input type="text"/>
Varicella Varivax Single Dose Vials - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text"/>	<input type="text"/>
Your location does not have a storage unit on file to support storage of this product. Required Storage: Frozen (-15C to -45C). <a href="#">Learn how to manage storage units.</a>									

# R54 Enhancement: Send Email when Order has been Created on Behalf of Provider

- When an order has been created on behalf of a provider, the provider will be notified via email.



# R54 Enhancement: Saving Draft Excursions

- Providers can now save excursions with minimum information:
  - Program Location Name
  - Contact
  - Was there vaccines involved in this excursion
  - Storage Unit
  - Excursion Start and End Time
  - Excursion Type

The screenshot shows a web form titled "VFA - Excursions" with the subtitle "Step 1 - Select Account and Enter Inventory Information". The form is divided into several sections:


- Location and Contact Information:**
  - Program Location:** A dropdown menu with the selected value "43 loc 2 vfc new - Vaccines for Adults".
  - Contact:** A search input field with the placeholder text "Enter Search Key".
- Excursion Information:**
  - Were there vaccines involved in this excursion?** Radio buttons for "Yes" and "No".
  - Was this stored in a storage unit or no storage unit involved?** Radio buttons for "Storage Unit" and "No Storage Unit Involved".
  - Excursion Start Date / Time:** Two input fields for "Date" and "Time".
  - Excursion End Date / Time:** Two input fields for "Date" and "Time".
  - Total Excursion time:** A single input field.
- Comments:** A large text area for entering notes.

A "Cancel" button is located at the bottom left of the form.



# R54 Enhancement: Only One Open Excursion Allowed at a Time

- Only one draft excursion can be opened at a time, providers will now have to submit the excursion in draft status before adding a new one.
- There will be a data update to mark any existing draft excursions with a Cancelled status.



# Next Steps for 2025 – 2026 VFC Flu Pre-Book

Allocation Period	Prebook Order Number	Program Location Name	Status	Close Date	Manage Prebook
Test Allocation Period - Janu...	PO-031395	MNHC - Excelsior Clinic - Vaccin...	Open	2025-04-03	<a href="#">View Prebook</a>
Test Allocation Period 2025-...	PO-038234	MNHC - Excelsior Clinic - Vaccin...	Open	2025-01-26	<a href="#">View Prebook</a>
25-26 VFC Flu UAT	PO-003679	MNHC - Excelsior Clinic - Vaccin...	Closed - Not Submitted	2025-01-10	<a href="#">View Prebook</a>
25-26 VFC Flu UAT	PO-003680	MNHC - Resource Center - Vacci...	Closed - Submitted	2025-01-10	<a href="#">View Prebook</a>

Provider Allocations Number	Product Name	Prebook Quantity
<a href="#">PA-029205</a>	FluMist 2025-2026 Intranasal Sprayer - 1...	500
<a href="#">PA-029206</a>	Fluzone 2025-2026 Single-Dose Syringe...	500

Allocation Period
25-26 VFC Flu UAT

Provider Allocations Number	Product Name	Prebook Quantity
PA-029205	FluMist 2025-2026 Intranasal Sprayer - 10 Per Box	500

Allocation Details	
Prebook Quantity	500
Total to be Allocated by CDPH	300
Remaining to be Allocated	0
Ordered	0
Available to Order	0


1. From the Prebook landing page, providers can click the **View Prebook** hyperlink corresponding to the appropriate Prebook order to access the **Prebook Order** page.
2. On the **Prebook Order** page, **Provider Allocation** details can be found in the **Related** tab. Providers can click the appropriate **Provider Allocation Number** hyperlink to access the **Provider Allocations** page.
3. In the **Details** tab on the **Provider Allocations** page, providers will find the approved pre-book amount in the **Total to be Allocated by CDPH** field (under the **Allocation Details** page section).

# 2025 Recertification Numbers

The following numbers reflect the 2025 Recertification completion progress by eligible Providers as of **February 6, 2025**.

## VFA Program

**799** completed recertifications  
**220** outstanding\* recertifications




## LHD 317 Program

**196** completed recertifications  
**88** outstanding\* recertifications



## VFC Program

**1,828** completed recertifications  
**1,514** outstanding\* recertifications



\*Outstanding Recertifications = In Progress, E-signature requested, In review, Follow Up

# Reminder: Complete the VFC Program Satisfaction Survey

- Feedback is important to help us understand what's working well, how to support participating providers and gain insight into challenges you are encountering while working with the VFC Program.
- Please take the time to submit feedback by completing the Satisfaction Survey!

**THANK YOU!**

# myCAvax – Known Issues and Workarounds



## Known Issues

- ✓ For providers placing orders through the community-side, please **refrain from using the trash can** at the very end of the row unless you wish to no longer order that vaccine at all during this ordering cycle and have no on-hand inventory to report
  - ✓ Instead, if you are looking to clear and re-enter your quantities, lot numbers, and/or expiration dates for your on-hand inventory, please do so by manually clearing the inputted data from the fields and, if necessary, using the smaller trash cans respective to each additionally added line of inventory



## Workaround / Next Steps

- ✓ If you accidentally used the trash can on a vaccine that you wish to order and/or report on-hand inventory for this ordering cycle and are now seeing the red error "a cancelled order cannot be changed." when trying to submit/save your order, please contact the PCC who can help get this order processed



Order

A cancelled order cannot be changed.



# Resources and Q&A

Leslie Amani and CDPH Subject Matter Experts

# Resources on EZIZ

- Home
- Vaccine Programs
- Vaccine Management
- Storage Units
- Temperature Monitoring
- Training & Webinars
- Clinic Resources
- Patient Resources

[Link to EZIZ Homepage](#)

**Home**  
Vaccine Programs  
Vaccine Management  
Storage Units  
Temperature Monitoring  
Training & Webinars  
Clinic Resources  
Patient Resources

**California's Vaccine Programs**

- VFC**  
California Vaccines for Children Program
- VFA**  
California Vaccines for Adults Program
- BAP**  
California Bridge Access Program
- LHD 317**  
Local Health Department 317 Program

**Ordering & Vaccine Management**

- myCAvax (VFC, VFA, BAP, and 317)
- MyVFCvaccines (read-only)

**Storage Requirements**

- Vaccine Storage Units
- Digital Data Loggers

**Alerts!**

**2024-25 COVID Vaccine**

- COVID-19 Vaccine Timing Guide (11/4/24)
- Calendario de la Vacuna COVID-19 (11/7/24)
- COVID-19 Vaccine Product Guide (9/9/24)
- More Resources: For Providers | For Patients
- Vaccine Ordering and Manufacturing Info

**VFC vaccine ordering and management is now live at myCAvax!**

myCAvax • Learn more about myCAvax move, recorded trainings and FAQs!

**Holiday Ordering and Distribution**

- Routine Vaccine Distribution Holiday Calendars & Holds
- SGF Calendar

**VFC Memos From CDPH**

**Vaccine Order Status**

**VFC Program Letters**

- 2025 Annual VFC Recertification December 19

**VFC Program Updates**

**Hot Topics**

**CDPH Immunization Updates for Providers**

- S&H Job Aids for VFC, VFA, LHD 317 and SGF programs
- Reporting & Return of Nonviable Vaccines
- Reporting Excursions & Manufacturer Contacts
- VFC and Birthing Hospitals

**Popular Resources**

**Protect Your Patients Against RSV!**

- RSV Immunization FAQs
- Resources for Providers and Patients

**Vaccine Resources**

- Vaccine Fact Sheets
- Flu
- Measles
- Mpox
- Pertussis
- Schedules & Recommendations
- For Pharmacies

**CDPH Applications**

- myCAvax (ordering and management)
- MyVFCvaccines (read-only)
- My Turn (COVID/Flu Vaccine Administration System)
- CAIR (California Immunization Registry)
- My DVR (Digital Vaccine Records)
- CAIR-ME (Medical Exemptions from Immunizations for School and Child Care)

# CDPH Office of Communications Toolkits

## CDPH Communication Toolkits

The screenshot shows the CDPH Office of Communications website. At the top left is the CDPH logo (California Department of Public Health). To the right is a search bar and navigation links: "I am looking for", "I am a", "Programs", and "A-Z Index". Below the navigation is a breadcrumb trail: "Home | Programs | Office of Communications | Infectious Diseases Toolkits". A dark blue banner reads "OFFICE OF COMMUNICATIONS".

On the left side, there is a list of categories: "Communications Toolkits", "Infectious Diseases", "Behavioral Health", "Health & Safety", "Emergency & Weather", and "A-Z Index". A dropdown menu is open under "Infectious Diseases", listing: "Bird Flu", "Flu & COVID-19", "Let's Talk Mpox", "Lyme Disease", "Measles", "Mpox", "Norovirus", "Respiratory Virus Prevention", "Routine Immunizations", "RSV", "Sexual Health", "Valley Fever", and "West Nile Virus".

The main content area features a "Disclaimer" section and two featured toolkit cards. The "Bird Flu" card has a blue header and a background image of silhouettes of cows and a sun. The "Routine Immunizations" card has a blue header and a background image of a young girl with a backpack.




# California Digital Vaccine Record (DVR)

If you're [wondering whether you're up to date on all your vaccines](#) or need immunization records for school/childcare entry or work, you can visit the [California Digital Vaccine Record](#) to access your full vaccination records.


If you need to catch up on your vaccines, talk with your health care provider or visit [MyTurn.ca.gov](https://www.myturn.ca.gov) to make your vaccine appointments.

Visit the [Routine Immunizations Communications Toolkit](#) for more messages to share.



# CDPH Office of Communications

Sign Up for the CDPH **Communications Tools & Information Newsletter**



Communication Tools & Information  
California Department of Public Health

Sign up to receive weekly email updates from the California Department of Public Health. Get the latest public health guidance and communications tools & resources for advancing public health in California and beyond.

First Name\*

Last Name\*

E-mail\*

Organization

Sign up to receive the [CDPH Office of Communications Tools & Information Newsletter](#)

# Vaccine Support

## Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: [myCAvax.hd@cdph.ca.gov](mailto:myCAvax.hd@cdph.ca.gov)
- For My Turn Clinic Help Desk inquiries: [MyTurn.Clinic.HD@cdph.ca.gov](mailto:MyTurn.Clinic.HD@cdph.ca.gov)
- For all other inquiries: [providercallcenter@cdph.ca.gov](mailto:providercallcenter@cdph.ca.gov)
- Phone: (833) 502-1245, Monday through Friday from 8:00 am – 5:00 pm

## myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.



Need help? View our job aids in the [Knowledge Center](#), or [contact us](#).



# COVID-19 Therapeutics Resources

Type of Support

Description

Updated 12.11.24



## General Information


[CDPH COVID-19 Treatments Webpage](#) (provides COVID-19 treatment information for healthcare providers and the general public)



## Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (Find COVID-19 medications at pharmacies, clinics, and other locations near you.)
- [Information Page for Test-to-Treat Program](#)



## Archive Therapeutic Webinars

For access to previously recorded webinars and slides, please contact:

[leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov)

Access previously recorded CDPH Immunization Branch Webinars for Providers, on the:

[CDPH Immunization Branch Webinar Site](#)



## Questions

For questions about ordering therapeutics, please email: [cdphtherapeutics@cdph.ca.gov](mailto:cdphtherapeutics@cdph.ca.gov)

# CDPH Provider Webinars and Trainings

## Week of February 3, 2025

	Monday 2/3	Tuesday 2/4	Wednesday 2/5	Thursday 2/6	Friday 2/7
Live Webinars and Training					<a href="#">CDPH Immunization Updates for Providers</a> 9:00 am – 10:30 am  <a href="#">My Turn Office Hours</a> 12:00 pm – 1:00 pm
View On Demand	<ul style="list-style-type: none"> <li><a href="#">CDPH Immunization Branch Archived Provider Webinars and Slides</a></li> <li><a href="#">AIM Vaccine Confidence Toolkit Webinar Series</a></li> </ul>		<ul style="list-style-type: none"> <li><a href="#">Introduction to My Turn Onboarding</a> (v. 1/4/22)</li> <li><a href="#">Latest Features in My Turn</a> (Requires myCAvax Login)</li> <li><a href="#">myCAvax Release Notes for LHD and CDPH Users</a> (Requires myCAvax Login)</li> </ul>		

Help	<b>Help Desk</b> <b>CDPH Provider Call Center:</b> 1-833-502-1245, M-F 8am-5pm <i>Email:</i> <a href="mailto:providercallcenter@cdph.ca.gov">providercallcenter@cdph.ca.gov</a> <b>My Turn:</b> <i>Help Desk Email:</i> <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a> <i>Onboarding Email:</i> <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a> <b>myCAvax:</b> <i>Help Desk Email:</i> <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a> <b>Mpox:</b> <i>Email:</i> <a href="mailto:stdcb@cdph.ca.gov">stdcb@cdph.ca.gov</a>		<b>Immunization Resources</b> <a href="#">California's General Immunization Resources (eziz.org)</a> <a href="#">RSV Immunization Resources</a> <a href="#">Flu Vaccination Resources</a> <a href="#">COVID-19 Vaccination Resources</a> <a href="#">COVID-19 Treatments</a> <a href="#">Mpox Vaccination Resources</a>	
------	---	--	---	--

# CDPH Provider Webinars and Trainings


## Week of February 10, 2025

	Monday 2/10	Tuesday 2/11	Wednesday 2/12	Thursday 2/13	Friday 2/14
Live Webinars and Training		<a href="#">My Turn Clinic Office Hour</a> 12:00 pm – 12:30 pm	<a href="#">Planning School-Located Adolescent Vaccination Events (SLVEs) for Spring 2025</a> 2:00 pm – 3:00 pm	<a href="#">NFID Webinar: Vaccines During Pregnancy: Protecting Maternal and Infant Health</a> 11:00 am – 12:00 pm	

View On Demand	<ul style="list-style-type: none"> <li><a href="#">CDPH Immunization Branch Archived Provider Webinars and Slides</a></li> <li><a href="#">AIM Vaccine Confidence Toolkit Webinar Series</a></li> </ul>	<ul style="list-style-type: none"> <li><a href="#">Introduction to My Turn Onboarding</a> (v. 1/4/22)</li> <li><a href="#">Latest Features in My Turn</a> (Requires myCAvax Login)</li> <li><a href="#">myCAvax Release Notes for LHD and CDPH Users</a> (Requires myCAvax Login)</li> </ul>
----------------	---	--

Help	Help Desk	Immunization Resources
	<p><b>CDPH Provider Call Center:</b> 1-833-502-1245, M-F 8am-5pm <i>Email:</i> <a href="mailto:providercallcenter@cdph.ca.gov">providercallcenter@cdph.ca.gov</a></p> <p><b>My Turn:</b> <i>Help Desk Email:</i> <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a>  <i>Onboarding Email:</i> <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a></p> <p><b>myCAvax:</b> <i>Help Desk Email:</i> <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a>      <b>Mpox:</b> <i>Email:</i> <a href="mailto:stdcb@cdph.ca.gov">stdcb@cdph.ca.gov</a></p>	<p><a href="#">California's General Immunization Resources (eziz.org)</a></p> <p><a href="#">RSV Immunization Resources</a>      <a href="#">Flu Vaccination Resources</a></p> <p><a href="#">COVID-19 Vaccination Resources</a>      <a href="#">COVID-19 Treatments</a></p> <p><a href="#">Mpox Vaccination Resources</a></p>

# Q&A



During today's webinar, please click and open the Q&A icon to ask your questions so CDPH panelists and subject matter experts (SMEs) can respond.



Thank you for attending!



Immunization  
Branch

Next CDPH Immunization Updates for Providers

**Friday, February 21, 2025**

**[CDPH Immunization Updates for Providers](#)**

**[Registration Link](#)**